Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021

Antifungal agents can have complex dosing and the potential for drug interaction, both of which can lead to subtherapeutic antifungal drug concentrations and poorer clinical outcomes for patients with haematological malignancy and haemopoietic stem cell transplant recipients. Antifungal agents can a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Internal medicine journal Ročník 51; číslo S7; s. 37 - 66
Hlavní autoři: Chau, Maggie M., Daveson, Kathryn, Alffenaar, Jan‐Willem C., Gwee, Amanda, Ho, Su Ann, Marriott, Deborah J. E., Trubiano, Jason A., Zhao, Jessie, Roberts, Jason A.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Melbourne John Wiley & Sons Australia, Ltd 01.11.2021
Wiley Subscription Services, Inc
Témata:
Antifungal Agents
antifungal therapy
Cytochrome P450
Dosage
Drug delivery
Drug dosages
Drug interaction
Drug Interactions
Drug metabolism
Drug Monitoring
Gene polymorphism
Hematologic Neoplasms - drug therapy
Hematology
Hematopoietic Stem Cell Transplantation
Humans
Malignancy
Patients
pharmacogenomics
Stem cell transplantation
therapeutic drug monitoring
Toxicity
toxicity
antifungal therapy
pharmacogenomics
drug interaction
therapeutic drug monitoring
ISSN:1444-0903, 1445-5994, 1445-5994
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Antifungal agents can have complex dosing and the potential for drug interaction, both of which can lead to subtherapeutic antifungal drug concentrations and poorer clinical outcomes for patients with haematological malignancy and haemopoietic stem cell transplant recipients. Antifungal agents can also be associated with significant toxicities when drug concentrations are too high. Suboptimal dosing can be minimised by clinical assessment, laboratory monitoring, avoidance of interacting drugs, and dose modification. Therapeutic drug monitoring (TDM) plays an increasingly important role in antifungal therapy, particularly for antifungal agents that have an established exposure‐response relationship with either a narrow therapeutic window, large dose‐exposure variability, cytochrome P450 gene polymorphism affecting drug metabolism, the presence of antifungal drug interactions or unexpected toxicity, and/or concerns for non‐compliance or inadequate absorption of oral antifungals. These guidelines provide recommendations on antifungal drug monitoring and TDM‐guided dosing adjustment for selected antifungal agents, and include suggested resources for identifying and analysing antifungal drug interactions. Recommended competencies for optimal interpretation of antifungal TDM and dose recommendations are also provided.
AbstractList Antifungal agents can have complex dosing and the potential for drug interaction, both of which can lead to subtherapeutic antifungal drug concentrations and poorer clinical outcomes for patients with haematological malignancy and haemopoietic stem cell transplant recipients. Antifungal agents can also be associated with significant toxicities when drug concentrations are too high. Suboptimal dosing can be minimised by clinical assessment, laboratory monitoring, avoidance of interacting drugs, and dose modification. Therapeutic drug monitoring (TDM) plays an increasingly important role in antifungal therapy, particularly for antifungal agents that have an established exposure‐response relationship with either a narrow therapeutic window, large dose‐exposure variability, cytochrome P450 gene polymorphism affecting drug metabolism, the presence of antifungal drug interactions or unexpected toxicity, and/or concerns for non‐compliance or inadequate absorption of oral antifungals. These guidelines provide recommendations on antifungal drug monitoring and TDM‐guided dosing adjustment for selected antifungal agents, and include suggested resources for identifying and analysing antifungal drug interactions. Recommended competencies for optimal interpretation of antifungal TDM and dose recommendations are also provided.
Antifungal agents can have complex dosing and the potential for drug interaction, both of which can lead to subtherapeutic antifungal drug concentrations and poorer clinical outcomes for patients with haematological malignancy and haemopoietic stem cell transplant recipients. Antifungal agents can also be associated with significant toxicities when drug concentrations are too high. Suboptimal dosing can be minimised by clinical assessment, laboratory monitoring, avoidance of interacting drugs, and dose modification. Therapeutic drug monitoring (TDM) plays an increasingly important role in antifungal therapy, particularly for antifungal agents that have an established exposure-response relationship with either a narrow therapeutic window, large dose-exposure variability, cytochrome P450 gene polymorphism affecting drug metabolism, the presence of antifungal drug interactions or unexpected toxicity, and/or concerns for non-compliance or inadequate absorption of oral antifungals. These guidelines provide recommendations on antifungal drug monitoring and TDM-guided dosing adjustment for selected antifungal agents, and include suggested resources for identifying and analysing antifungal drug interactions. Recommended competencies for optimal interpretation of antifungal TDM and dose recommendations are also provided.Antifungal agents can have complex dosing and the potential for drug interaction, both of which can lead to subtherapeutic antifungal drug concentrations and poorer clinical outcomes for patients with haematological malignancy and haemopoietic stem cell transplant recipients. Antifungal agents can also be associated with significant toxicities when drug concentrations are too high. Suboptimal dosing can be minimised by clinical assessment, laboratory monitoring, avoidance of interacting drugs, and dose modification. Therapeutic drug monitoring (TDM) plays an increasingly important role in antifungal therapy, particularly for antifungal agents that have an established exposure-response relationship with either a narrow therapeutic window, large dose-exposure variability, cytochrome P450 gene polymorphism affecting drug metabolism, the presence of antifungal drug interactions or unexpected toxicity, and/or concerns for non-compliance or inadequate absorption of oral antifungals. These guidelines provide recommendations on antifungal drug monitoring and TDM-guided dosing adjustment for selected antifungal agents, and include suggested resources for identifying and analysing antifungal drug interactions. Recommended competencies for optimal interpretation of antifungal TDM and dose recommendations are also provided.
Author Zhao, Jessie
Chau, Maggie M.
Daveson, Kathryn
Marriott, Deborah J. E.
Alffenaar, Jan‐Willem C.
Gwee, Amanda
Trubiano, Jason A.
Ho, Su Ann
Roberts, Jason A.
Author_xml – sequence: 1
  givenname: Maggie M.
  surname: Chau
  fullname: Chau, Maggie M.
  organization: The Royal Melbourne Hospital
– sequence: 2
  givenname: Kathryn
  surname: Daveson
  fullname: Daveson, Kathryn
  organization: The Canberra Hospital
– sequence: 3
  givenname: Jan‐Willem C.
  surname: Alffenaar
  fullname: Alffenaar, Jan‐Willem C.
  organization: University of Sydney
– sequence: 4
  givenname: Amanda
  surname: Gwee
  fullname: Gwee, Amanda
  organization: Murdoch Children's Research Institute
– sequence: 5
  givenname: Su Ann
  surname: Ho
  fullname: Ho, Su Ann
  organization: Peter MacCallum Cancer Centre
– sequence: 6
  givenname: Deborah J. E.
  surname: Marriott
  fullname: Marriott, Deborah J. E.
  organization: The University of New South Wales
– sequence: 7
  givenname: Jason A.
  surname: Trubiano
  fullname: Trubiano, Jason A.
  organization: The University of Melbourne
– sequence: 8
  givenname: Jessie
  surname: Zhao
  fullname: Zhao, Jessie
  organization: The Alfred Hospital
– sequence: 9
  givenname: Jason A.
  surname: Roberts
  fullname: Roberts, Jason A.
  email: j.roberts2@uq.edu.au
  organization: Nîmes University Hospital, University of Montpellier
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34937141$$D View this record in MEDLINE/PubMed
BookMark eNp9kk1v1DAQhiNURD_gwB9AlriAxLb22k7sY7Xio6iIC5wjrzNJZ5XYwXa27P_kB-FsCodK4ItHmmdej-ed8-LEeQdF8ZLRS5bPFQ67Syalqp4UZ0wIuZJai5NjLFZUU35anMe4o5RVXItnxSkXmldMsLPi18a7CC5OkXQTNtCjg0haH4gfEw4Y0XXEuITt5DrTkyZMHZmxPYRDTjRk8A6TDzOXPDF7j00OfqLFtAA4jMHvgfgpWT9kdXRkNAnBpUjuMd2ROwODSb73Hdr8xmB67Jxxdqmfs370CAktiQkGYqHvSQrGxbHPvZEAFsej3juypmv2vHjamj7Ci4f7ovj-4f23zafV7dePN5vr25XlSlUroJIzrWRpVcUFb62VsqFGy21lgSujhLTSNoIyzSUovjXaltyA1Bbakpf8oniz6OYP_pggpjoPbG7OOPBTrNcl42ullWIZff0I3fkpuNzdTK1FmX2kmXr1QE3bAZp6DDiYcKj_-JWBtwtgg48xQPsXYbSed6HOu1AfdyGzV4_YbEmeu3d5dNj_r-Ieezj8W7q--fJ5qfgNwyvKVw
CitedBy_id crossref_primary_10_1093_jacamr_dlae184
crossref_primary_10_1093_mmy_myad054
crossref_primary_10_1111_imj_15593
crossref_primary_10_1111_imj_15592
crossref_primary_10_1111_imj_15591
crossref_primary_10_1111_tid_14197
crossref_primary_10_1093_mmy_myaf074
crossref_primary_10_1002_bcp_70026
crossref_primary_10_1111_imj_15590
crossref_primary_10_3389_fmed_2025_1625697
crossref_primary_10_3390_jcm12144637
crossref_primary_10_3389_fphar_2024_1439586
crossref_primary_10_1080_14656566_2024_2387686
crossref_primary_10_1080_14787210_2024_2409408
crossref_primary_10_1093_jac_dkac060
crossref_primary_10_1016_j_farma_2022_11_001
crossref_primary_10_1080_10428194_2022_2126282
crossref_primary_10_1007_s15010_025_02572_2
crossref_primary_10_1111_imj_15589
crossref_primary_10_1111_imj_15588
crossref_primary_10_1093_ofid_ofad468
crossref_primary_10_1002_phar_2850
crossref_primary_10_1182_bloodadvances_2025016212
crossref_primary_10_3390_jof9080805
crossref_primary_10_3389_fphar_2024_1368274
crossref_primary_10_1111_imj_15586
crossref_primary_10_1111_imj_15585
crossref_primary_10_1093_jac_dkaf005
crossref_primary_10_1093_jac_dkae473
crossref_primary_10_1093_jac_dkaf044
crossref_primary_10_1016_j_farma_2022_12_008
crossref_primary_10_1080_17512433_2024_2317293
crossref_primary_10_1111_tid_14129
crossref_primary_10_1016_j_inoche_2025_115301
crossref_primary_10_1016_j_bjid_2025_104517
crossref_primary_10_1007_s12281_022_00430_4
crossref_primary_10_1016_j_idc_2025_01_001
crossref_primary_10_1097_FPC_0000000000000536
crossref_primary_10_1016_j_leukres_2023_107341
crossref_primary_10_1093_cid_ciaf258
crossref_primary_10_3390_pharmaceutics16050677
crossref_primary_10_1093_cid_ciaf256
crossref_primary_10_1080_10428194_2022_2142054
crossref_primary_10_1007_s00063_025_01265_w
crossref_primary_10_1186_s40780_025_00427_4
crossref_primary_10_1002_jppr_1924
crossref_primary_10_1128_cmr_00004_23
crossref_primary_10_1111_imj_16571
crossref_primary_10_1158_0008_5472_CAN_24_1609
crossref_primary_10_3389_fphar_2025_1443487
crossref_primary_10_1093_jac_dkae099
crossref_primary_10_1093_jac_dkad085
Cites_doi 10.1016/j.ejps.2004.01.005
10.1002/phar.1566
10.1056/NEJM199903113401004
10.2147/tcrm.2007.3.1.71
10.1097/FTD.0b013e31823cef77
10.1086/524669
10.1128/AAC.01489-16
10.1046/j.1439-0507.1999.00518.x
10.1093/jac/dkm389
10.1128/AAC.02516-17
10.1136/bjo.86.7.829-a
10.1016/j.mmcr.2017.05.004
10.1086/508774
10.1128/AAC.02130-17
10.1016/j.jinf.2019.02.013
10.1111/myc.13084
10.1007/s10096-016-2780-z
10.1111/petr.13777
10.1093/jac/dkn409
10.1128/AAC.01325-10
10.1111/j.1468-1293.2009.00778.x
10.1007/s40588-015-0019-x
10.1128/AAC.2.3.114
10.1111/j.1469-0691.1997.tb00269.x
10.1111/imj.15586
10.1093/jac/dkx440
10.1093/cid/ciy827
10.1093/jac/dkw127
10.1007/s00228-008-0574-7
10.1086/374850
10.2165/11315570-000000000-00000
10.1086/511685
10.1128/AAC.00172-10
10.1111/myc.12871
10.1007/s00228-014-1733-7
10.1080/14787210.2016.1207526
10.1001/archdermatol.2009.362
10.1182/blood-2012-01-403030
10.1128/AAC.00216-13
10.1086/423381
10.1136/bmj.322.7286.579
10.1086/514672
10.1586/14787210.2016.1128822
10.1177/0091270005283837
10.1093/cid/ciw326
10.1177/1078155217722405
10.1007/BF00199879
10.1016/S0140-6736(05)67490-9
10.1007/s12281-017-0287-4
10.1093/jac/dkx354
10.5863/1551-6776-25.1.47
10.1093/jac/dkx263
10.1056/NEJMoa061098
10.1056/NEJM200201243460403
10.1038/sj.bmt.1704516
10.1111/j.1469-0691.2009.02990.x
10.1056/NEJMoa040446
10.1016/j.jinf.2006.03.003
10.1128/AAC.01435-19
10.1016/j.ijid.2016.12.014
10.1016/S1473-3099(16)00071-2
10.1128/AAC.05219-11
10.1186/s13054-015-0758-3
10.1128/AAC.01088-16
10.1038/bmt.2009.334
10.1016/j.bbmt.2012.03.014
10.1111/j.1399-3062.2004.00065.x
10.1111/myc.12199
10.1210/js.2019-00189
10.1177/0091270008327537
10.1128/AAC.1.6.476
10.1007/s13318-018-0519-1
10.1097/RLU.0b013e31820902d8
10.1128/AAC.01034-08
10.1016/S0002-9343(99)00457-X
10.1093/jac/dkz303
10.1080/17425255.2019.1671971
10.1128/AAC.50.2.632-638.2006
10.1111/myc.12326
10.1128/AAC.00949-10
10.1086/324620
10.1111/j.1600-6143.2009.02837.x
10.1182/blood-2003-08-2644
10.1345/aph.1G741
10.1592/phco.31.2.214
10.1128/AAC.02605-17
10.1056/NEJMoa021585
10.1034/j.1399-3062.2002.t01-2-02002.x
10.1016/j.cmi.2018.01.002
10.1086/377131
10.1128/AAC.01034-17
10.1086/423378
10.1177/1078155218786028
10.1016/S0002-9343(02)01191-9
10.1097/QCO.0000000000000611
10.1128/AAC.01723-18
10.1093/jac/dkp464
10.1128/AAC.11.2.244
10.1111/bcp.13628
10.1128/AAC.01316-08
10.1093/jac/dkx029
10.1046/j.1365-2141.1997.2473063.x
10.1093/cid/ciz741
10.1046/j.1365-2141.1999.01465.x
10.1182/blood-2005-06-2564
10.3928/01477447-20110922-35
10.1016/0002-9343(94)90023-X
10.1200/JCO.2003.04.052
10.1128/AAC.43.8.1955
10.1517/17425255.2011.615309
10.1111/myc.12731
10.1517/14740338.2013.829036
10.1046/j.1439-0507.1999.00505.x
10.1056/NEJM199411173312001
10.1128/AAC.00626-12
10.1128/AAC.47.9.2788-2795.2003
10.1128/AAC.00702-11
10.1086/374557
10.1128/AAC.32.3.369
10.1128/AAC.01027-09
10.7326/0003-4819-138-9-200305060-00006
10.1111/fcp.12212
10.1128/AAC.00229-16
10.1002/cpdd.588
10.1097/QCO.0b013e3283184611
10.1128/AAC.00496-15
10.1038/bmt.2013.87
10.1128/AAC.05900-11
10.1038/bmt.2009.17
10.1093/jac/dkw099
10.1056/NEJMoa061094
10.1128/AAC.48.3.815-823.2004
10.1093/jac/dkv380
10.1128/AAC.00484-19
10.1128/AAC.35.4.707
10.1128/AAC.00760-17
10.1128/AAC.02353-18
10.1128/AAC.02655-17
10.1093/jac/dku529
10.1016/j.mmcr.2013.04.001
10.1111/imj.12594
10.1111/j.1365-2710.2011.01309.x
10.1111/myc.13028
10.1093/clinids/20.4.755
10.1159/000007260
10.1093/ofid/ofv133.527
10.1136/pgmj.55.647.667
10.1086/323401
10.1128/CMR.00046-13
10.1093/jac/dkx295
10.1093/jac/dkx228
10.1086/588844
10.1517/17425255.3.4.573
10.1111/myc.12339
10.1093/jac/dkx122
10.1016/S0140-6736(07)60605-9
10.1111/j.1365-2710.2007.00812.x
10.1128/AAC.01284-09
10.1093/jac/dkw047
10.1007/s10096-012-1754-z
10.1007/s00277-015-2545-2
10.1111/j.1439-0507.2011.02116.x
10.1086/422312
10.1186/s12879-018-3055-3
10.1093/jac/dkz546
10.1097/MPH.0b013e3182880eaa
10.1093/ndt/gfg363
10.1016/0959-8049(95)00619-2
10.1038/clpt.2010.64
10.1016/S0002-9343(96)80072-6
10.1038/ki.1991.214
10.1128/AAC.47.10.3165-3169.2003
10.1002/phar.1631
10.1038/sj.bmt.1701270
10.2217/pgs.14.53
10.1002/j.1875-9114.1990.tb02593.x
10.1111/jcpt.12078
10.1111/myc.12452
10.1128/AAC.01221-08
10.1136/jcp.50.6.477
10.1038/sj.bmt.1705754
10.1016/j.drup.2014.06.001
10.2147/TCRM.S203625
10.2165/00003088-200544100-00002
10.1128/AAC.00802-12
10.1097/RHU.0b013e31820aff12
10.1002/cpt.620
10.1086/520980
10.1093/jac/46.2.171
10.1128/AAC.03050-14
10.1128/AAC.49.4.1331-1336.2005
10.1034/j.1399-3062.2002.01004.x
10.1016/j.jaad.2009.09.033
10.2165/11585270-000000000-00000
10.1097/00000441-198911000-00004
10.1007/s40262-018-0658-1
10.1128/AAC.42.7.1738
10.1016/j.cmi.2020.03.008
10.1177/1078155217748471
10.1186/1471-2407-10-679
10.1002/14651858.CD000969
10.1128/AAC.50.2.658-666.2006
10.1186/s13054-014-0657-z
10.2174/1389200215666141125121511
10.1155/2014/340586
10.1111/bcp.13789
10.1128/AAC.00705-18
10.1007/s10792-012-9696-0
10.1248/bpb.27.1154
10.1128/AAC.00394-13
10.1345/aph.1H671
10.1093/cid/ciu657
10.1124/dmd.32.2.267
10.1093/jac/dkaa382
10.1086/313498
10.1093/clinids/12.Supplement_3.S318
10.1016/0002-9343(87)90691-7
10.1097/FTD.0b013e3181ea3de6
10.1128/AAC.01194-17
10.1128/AAC.41.12.2714
10.1155/2010/351084
10.1093/clind/15.6.1003
10.1002/cpt.583
10.1136/bjo.2007.136515
10.1093/mmy/myz012
10.1093/jac/dkp416
10.1111/myc.12749
10.1128/AAC.37.6.1270
10.1097/QCO.0b013e328359a56e
10.1007/s12281-016-0255-4
10.1016/S0140-6736(15)01159-9
10.1086/317451
10.1128/AAC.32.9.1310
10.2147/DHPS.S140213
10.1093/jac/dkm023
10.1201/b13787-151
10.1111/imj.12600
10.1111/jcpt.12046
10.1186/s12941-017-0235-8
10.1093/jac/dkx447
10.1128/AAC.00701-16
10.1002/j.1875-9114.1998.tb03856.x
10.1007/s10096-005-0080-0
10.1097/QCO.0000000000000497
10.1007/s40265-020-01306-y
10.1128/AAC.45.10.2845-2855.2001
10.1097/FTD.0000000000000235
10.1111/j.1600-0609.2004.00239.x
10.1111/bcp.13707
10.1517/14656566.6.13.2231
10.1128/AAC.00296-07
10.1128/AAC.28.5.648
10.1093/cid/ciq188
10.1056/NEJMoa066906
10.1111/myc.12948
10.7326/0003-4819-135-6-200109180-00010
10.1093/jac/dkz188
10.1002/j.1552-4604.1988.tb03159.x
10.1128/AAC.31.1.6
10.1086/598327
10.1111/myc.12524
10.1128/AAC.01083-10
10.1177/1078155216673228
10.1086/341401
10.1046/j.1365-2125.2003.01994.x
10.1093/cid/cis599
10.1128/AAC.42.6.1512
10.1093/jac/dkl009
10.1086/515129
10.1086/504328
10.1002/pbc.25568
10.1016/j.ijantimicag.2020.106180
10.1093/jac/dkv350
10.1093/ckj/sfx156
10.1128/AAC.05000-14
10.1128/AAC.00700-12
10.1093/jac/dkt508
10.1086/605499
10.1097/FTD.0000000000000175
10.1097/FTD.0000000000000334
10.1002/jppr.1378
10.1080/10428190802635500
10.1086/341662
10.1128/AAC.14.2.270
10.1128/AAC.49.8.3171-3177.2005
10.1128/AAC.05937-11
10.1002/cpt.1012
ContentType Journal Article
Contributor Slavin, Monica A
Thursky, Karin A
Roberts, Jason A
Blyth, Christopher C
Morrissey, C Orla
Chen, Sharon C-A
Chang, Christina C
Worth, Leon J
Khanina, Anna
Contributor_xml – sequence: 1
  givenname: Monica A
  surname: Slavin
  fullname: Slavin, Monica A
– sequence: 2
  givenname: Karin A
  surname: Thursky
  fullname: Thursky, Karin A
– sequence: 3
  givenname: Jason A
  surname: Roberts
  fullname: Roberts, Jason A
– sequence: 4
  givenname: Leon J
  surname: Worth
  fullname: Worth, Leon J
– sequence: 5
  givenname: Christina C
  surname: Chang
  fullname: Chang, Christina C
– sequence: 6
  givenname: Sharon C-A
  surname: Chen
  fullname: Chen, Sharon C-A
– sequence: 7
  givenname: C Orla
  surname: Morrissey
  fullname: Morrissey, C Orla
– sequence: 8
  givenname: Christopher C
  surname: Blyth
  fullname: Blyth, Christopher C
– sequence: 9
  givenname: Anna
  surname: Khanina
  fullname: Khanina, Anna
Copyright 2021 Royal Australasian College of Physicians.
2021 Royal Australasian College of Physicians
Copyright_xml – notice: 2021 Royal Australasian College of Physicians.
– notice: 2021 Royal Australasian College of Physicians
CorporateAuthor Australasian Antifungal Guidelines Steering Committee
CorporateAuthor_xml – name: Australasian Antifungal Guidelines Steering Committee
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7U9
H94
K9.
7X8
DOI 10.1111/imj.15587
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Virology and AIDS Abstracts
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE
AIDS and Cancer Research Abstracts
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1445-5994
EndPage 66
ExternalDocumentID 34937141
10_1111_imj_15587
IMJ15587
Genre article
Journal Article
GrantInformation_xml – fundername: Australian National Health and Medical Research Council
  funderid: APP1117065; APP1099452
– fundername: Australian National Health and Medical Research Council
  grantid: APP1117065
– fundername: Australian National Health and Medical Research Council
  grantid: APP1099452
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
29J
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAWTL
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABJNI
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEFGJ
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AIACR
AIDQK
AIDYY
AIQQE
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EMOBN
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
J5H
K48
KBYEO
KTM
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
RJQFR
ROL
RX1
SUPJJ
TEORI
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOQ
WOW
WQJ
WVDHM
WXI
WXSBR
XG1
YFH
ZGI
ZZTAW
~IA
~WT
AAYXX
CITATION
O8X
AAHHS
ACCFJ
ADZOD
AEEZP
AEQDE
AEUQT
AFPWT
AIWBW
AJBDE
CGR
CUY
CVF
ECM
EIF
ESX
NPM
WRC
7T5
7U9
H94
K9.
7X8
ID FETCH-LOGICAL-c3887-e05319856c87343fcc55d0a95b7ce38a845c5cd401935e83ba9c63ae59cef6363
IEDL.DBID DRFUL
ISICitedReferencesCount 53
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000732933900004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1444-0903
1445-5994
IngestDate Thu Oct 02 12:54:56 EDT 2025
Tue Oct 07 07:13:08 EDT 2025
Wed Feb 19 02:25:42 EST 2025
Sat Nov 29 05:53:06 EST 2025
Tue Nov 18 22:18:31 EST 2025
Sun Sep 21 06:22:53 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue S7
Keywords toxicity
antifungal therapy
pharmacogenomics
drug interaction
therapeutic drug monitoring
Language English
License 2021 Royal Australasian College of Physicians.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3887-e05319856c87343fcc55d0a95b7ce38a845c5cd401935e83ba9c63ae59cef6363
Notes Australasian Antifungal Guidelines Steering Committee: Christina C Chang, Christopher C Blyth, Sharon C‐A Chen, Anna Khanina, C. Orla Morrissey, Jason A. Roberts, Karin A Thursky, Leon Worth, Monica A Slavin.
Conflict of interest: The following working group members are consultants or advisory committee members or receive honoraria, fees for service, or travel assistance from; or have research or other associations with the organisations listed: J. A. Roberts – Pfizer, Sandoz, Wolters Kluwer, Merck, Sharpe & Dohme, QPEX, Discuva Ltd., Accelerate Diagnostics, Bayer, Biomerieux, Cipla, The Medicines Company, Cardeas Pharma; A. Gwee – Merck, Sharpe & Dohme; J. A. Trubiano – Merck, Sharpe & Dohme.
Funding: J. A. Roberts would like to acknowledge funding from the Australian National Health and Medical Research Council for a Centre of Research Excellence (APP1099452) and a Practitioner Fellowship (APP1117065).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/imj.15587
PMID 34937141
PQID 2612461110
PQPubID 2045147
PageCount 30
ParticipantIDs proquest_miscellaneous_2613289881
proquest_journals_2612461110
pubmed_primary_34937141
crossref_primary_10_1111_imj_15587
crossref_citationtrail_10_1111_imj_15587
wiley_primary_10_1111_imj_15587_IMJ15587
PublicationCentury 2000
PublicationDate November 2021
2021-11-00
2021-Nov
20211101
PublicationDateYYYYMMDD 2021-11-01
PublicationDate_xml – month: 11
  year: 2021
  text: November 2021
PublicationDecade 2020
PublicationPlace Melbourne
PublicationPlace_xml – name: Melbourne
– name: Australia
– name: Hoboken
PublicationTitle Internal medicine journal
PublicationTitleAlternate Intern Med J
PublicationYear 2021
Publisher John Wiley & Sons Australia, Ltd
Wiley Subscription Services, Inc
Publisher_xml – name: John Wiley & Sons Australia, Ltd
– name: Wiley Subscription Services, Inc
References 2004; 21
1987; 31
2004; 27
2019; 15
2004; 6
2016; 30
1999; 43
1999; 42
2012; 18
2001; 45
1997; 3
2016; 38
2004; 32
1995; 20
2017; 72
1998; 18
2001; 135
2021; 76
2002; 86
2013; 57
2004; 39
2004; 34
2019; 25
2008; 21
2012; 25
2017; 61
2009; 69
2010; 2010
2009; 65
2019; 32
1999; 29
1999; 28
2004; 48
2018; 104
1999; 340
2016; 10
2012; 37
2016; 16
2012; 34
1999; 105
2021; 51
2016; 14
2011; 7
2019; 44
2017; 55
2008; 47
2015; 2015
2020; 26
2005; 6
2008; 46
2020; 25
2020; 24
2001; 33
2006; 107
2010; 54
1990; 10
1994; 331
2014; 70
1990; 12
2020; 63
2017; 47
2019; 57
2002; 113
2010; 146
2019; 58
2014; 69
2018; 84
2020; 56
2007; 32
1996; 101
2010; 62
2010; 65
2004; 72
2019; 62
2017; 36
1997; 98
1987; 83
2019; 63
1996; 32a
2019; 68
1991; 40
2014; 59
2002; 346
2014; 58
2002; 347
2014; 57
2018; 73
2008; 61
2008; 62
2015; 2
2013; 48
2019; 70
2007; 369
2012
1991; 35
2019; 74
2010
2002; 34
2002; 35
2019; 78
2020; 80
1989; 298
1978; 17
2018; 62
1978; 14
2018; 61
2007; 51
2008; 92
1979; 55
2007; 59
2007; 356
2010; 88
2013; 38
2020; 75
2013; 33
2013; 32
2019; 85
2013; 35
2017; 17
2017; 16
2017; 11
2009; 9
2017
2007; 40
2007; 41
2017; 101
2007; 44
2017; 102
2007; 45
2010; 11
1985; 28
2010; 10
2012; 120
2010; 16
2013; 2
2015; 70
1997; 41
2014; 27
2011; 52
2016; 387
2011; 55
2014; 25
2013; 7
2003; 56
1993; 37
1997; 50
2011; 71
2006; 25
1987
2014; 15
2003; 47
2014; 13
2014; 18
2007; 3
2014; 17
2018; 31
2019; 8
2001; 322
2015; 59
2010; 32
2015; 58
2019; 3
2006; 53
2006; 50
2006; 57
2003; 36
2003; 37
2002; 4
2016; 95
2014; 44
2018; 24
2010; 45
2018; 18
2006; 42
2006; 40
2006; 46
2015; 62
2005; 366
2000; 108
1988; 28
1977; 11
2018; 11
2003; 21
1994; 97
2015; 35
2009; 44
2015; 37
2000; 3
2000; 46
1988; 32
2016; 71
2003; 18
1992; 15
2011; 17
2012; 56
2012; 55
1998; 42
2009; 49
2017; 9
2009; 48
2009; 53
2002; 186
2009; 50
1998; 27
2004; 103
2015; 19
2003; 138
2011; 31
1994; 46
2011; 34
2011; 36
2005; 49
1998; 21
2016; 59
2005; 44
1972; 1
1972; 2
2004; 351
2000; 31
2016; 63
2016; 60
e_1_2_14_73_1
e_1_2_14_96_1
e_1_2_14_110_1
e_1_2_14_280_1
e_1_2_14_50_1
e_1_2_14_35_1
e_1_2_14_12_1
e_1_2_14_265_1
e_1_2_14_288_1
e_1_2_14_239_1
e_1_2_14_58_1
e_1_2_14_216_1
e_1_2_14_182_1
e_1_2_14_242_1
e_1_2_14_6_1
e_1_2_14_121_1
e_1_2_14_107_1
e_1_2_14_144_1
e_1_2_14_167_1
Tutle L (e_1_2_14_258_1) 2017
e_1_2_14_85_1
e_1_2_14_129_1
e_1_2_14_291_1
e_1_2_14_62_1
e_1_2_14_24_1
e_1_2_14_227_1
e_1_2_14_276_1
e_1_2_14_299_1
e_1_2_14_47_1
e_1_2_14_230_1
e_1_2_14_253_1
e_1_2_14_193_1
e_1_2_14_170_1
e_1_2_14_119_1
e_1_2_14_132_1
e_1_2_14_302_1
e_1_2_14_155_1
e_1_2_14_178_1
e_1_2_14_72_1
e_1_2_14_95_1
e_1_2_14_111_1
e_1_2_14_301_1
e_1_2_14_11_1
e_1_2_14_34_1
e_1_2_14_57_1
e_1_2_14_264_1
e_1_2_14_215_1
e_1_2_14_238_1
e_1_2_14_287_1
e_1_2_14_241_1
e_1_2_14_181_1
cr-split#-e_1_2_14_204_1.1
cr-split#-e_1_2_14_204_1.2
e_1_2_14_120_1
e_1_2_14_143_1
e_1_2_14_7_1
e_1_2_14_108_1
e_1_2_14_166_1
e_1_2_14_189_1
e_1_2_14_84_1
e_1_2_14_128_1
e_1_2_14_100_1
e_1_2_14_290_1
e_1_2_14_61_1
e_1_2_14_23_1
e_1_2_14_46_1
e_1_2_14_275_1
e_1_2_14_203_1
e_1_2_14_249_1
e_1_2_14_298_1
e_1_2_14_69_1
e_1_2_14_226_1
e_1_2_14_252_1
e_1_2_14_192_1
e_1_2_14_131_1
e_1_2_14_154_1
e_1_2_14_177_1
e_1_2_14_75_1
e_1_2_14_52_1
e_1_2_14_90_1
e_1_2_14_282_1
e_1_2_14_218_1
e_1_2_14_14_1
e_1_2_14_98_1
e_1_2_14_267_1
e_1_2_14_37_1
e_1_2_14_221_1
e_1_2_14_244_1
e_1_2_14_161_1
e_1_2_14_184_1
e_1_2_14_123_1
e_1_2_14_169_1
e_1_2_14_105_1
e_1_2_14_146_1
e_1_2_14_41_1
e_1_2_14_64_1
e_1_2_14_4_1
e_1_2_14_293_1
cr-split#-e_1_2_14_36_1.2
cr-split#-e_1_2_14_36_1.1
e_1_2_14_229_1
e_1_2_14_87_1
e_1_2_14_49_1
e_1_2_14_206_1
e_1_2_14_278_1
e_1_2_14_26_1
e_1_2_14_232_1
e_1_2_14_255_1
e_1_2_14_172_1
e_1_2_14_304_1
e_1_2_14_195_1
e_1_2_14_117_1
e_1_2_14_134_1
e_1_2_14_157_1
e_1_2_14_74_1
e_1_2_14_97_1
e_1_2_14_51_1
e_1_2_14_281_1
e_1_2_14_13_1
e_1_2_14_266_1
e_1_2_14_59_1
e_1_2_14_289_1
e_1_2_14_243_1
e_1_2_14_160_1
e_1_2_14_183_1
e_1_2_14_220_1
e_1_2_14_5_1
Stott KE (e_1_2_14_217_1) 2018; 62
e_1_2_14_145_1
e_1_2_14_168_1
e_1_2_14_106_1
e_1_2_14_86_1
e_1_2_14_63_1
e_1_2_14_40_1
e_1_2_14_292_1
cr-split#-e_1_2_14_32_1.2
e_1_2_14_228_1
e_1_2_14_277_1
Chapman J (e_1_2_14_296_1) 2012
e_1_2_14_25_1
cr-split#-e_1_2_14_32_1.1
e_1_2_14_48_1
e_1_2_14_205_1
e_1_2_14_254_1
e_1_2_14_171_1
e_1_2_14_194_1
e_1_2_14_231_1
e_1_2_14_303_1
e_1_2_14_133_1
e_1_2_14_179_1
e_1_2_14_114_1
e_1_2_14_137_1
Kunka ME (e_1_2_14_259_1) 2015; 2015
e_1_2_14_92_1
e_1_2_14_261_1
e_1_2_14_284_1
e_1_2_14_54_1
e_1_2_14_39_1
e_1_2_14_77_1
e_1_2_14_16_1
e_1_2_14_200_1
e_1_2_14_223_1
e_1_2_14_246_1
e_1_2_14_140_1
e_1_2_14_186_1
e_1_2_14_163_1
e_1_2_14_125_1
e_1_2_14_103_1
e_1_2_14_148_1
e_1_2_14_2_1
e_1_2_14_20_1
e_1_2_14_81_1
e_1_2_14_208_1
e_1_2_14_272_1
e_1_2_14_295_1
e_1_2_14_43_1
e_1_2_14_66_1
e_1_2_14_28_1
e_1_2_14_89_1
e_1_2_14_211_1
e_1_2_14_234_1
e_1_2_14_257_1
e_1_2_14_269_1
e_1_2_14_151_1
e_1_2_14_197_1
e_1_2_14_174_1
cr-split#-e_1_2_14_122_1.1
e_1_2_14_115_1
cr-split#-e_1_2_14_122_1.2
e_1_2_14_136_1
e_1_2_14_306_1
e_1_2_14_159_1
e_1_2_14_30_1
e_1_2_14_53_1
e_1_2_14_91_1
e_1_2_14_260_1
e_1_2_14_219_1
e_1_2_14_283_1
e_1_2_14_15_1
e_1_2_14_38_1
e_1_2_14_76_1
e_1_2_14_99_1
e_1_2_14_268_1
e_1_2_14_222_1
Walsh A (e_1_2_14_285_1) 1978; 17
e_1_2_14_162_1
e_1_2_14_185_1
e_1_2_14_124_1
e_1_2_14_147_1
e_1_2_14_104_1
e_1_2_14_42_1
e_1_2_14_80_1
e_1_2_14_3_1
e_1_2_14_271_1
e_1_2_14_207_1
e_1_2_14_294_1
e_1_2_14_65_1
e_1_2_14_27_1
e_1_2_14_88_1
Heykants J (e_1_2_14_270_1) 1987
e_1_2_14_279_1
e_1_2_14_210_1
e_1_2_14_256_1
e_1_2_14_233_1
e_1_2_14_150_1
cr-split#-e_1_2_14_31_1.2
e_1_2_14_305_1
cr-split#-e_1_2_14_31_1.1
e_1_2_14_173_1
e_1_2_14_196_1
e_1_2_14_116_1
e_1_2_14_135_1
e_1_2_14_158_1
e_1_2_14_94_1
e_1_2_14_112_1
e_1_2_14_139_1
e_1_2_14_300_1
e_1_2_14_71_1
e_1_2_14_10_1
e_1_2_14_56_1
e_1_2_14_263_1
e_1_2_14_286_1
e_1_2_14_33_1
e_1_2_14_214_1
e_1_2_14_79_1
e_1_2_14_237_1
e_1_2_14_202_1
e_1_2_14_180_1
e_1_2_14_240_1
e_1_2_14_165_1
e_1_2_14_8_1
e_1_2_14_109_1
e_1_2_14_142_1
e_1_2_14_188_1
e_1_2_14_60_1
e_1_2_14_83_1
e_1_2_14_127_1
e_1_2_14_101_1
e_1_2_14_45_1
e_1_2_14_68_1
e_1_2_14_274_1
e_1_2_14_297_1
e_1_2_14_22_1
e_1_2_14_225_1
e_1_2_14_248_1
e_1_2_14_19_1
e_1_2_14_213_1
cr-split#-e_1_2_14_118_1.2
cr-split#-e_1_2_14_245_1.1
cr-split#-e_1_2_14_118_1.1
e_1_2_14_251_1
e_1_2_14_191_1
e_1_2_14_130_1
e_1_2_14_176_1
e_1_2_14_153_1
cr-split#-e_1_2_14_245_1.2
e_1_2_14_199_1
e_1_2_14_113_1
e_1_2_14_138_1
e_1_2_14_70_1
e_1_2_14_262_1
e_1_2_14_55_1
e_1_2_14_17_1
e_1_2_14_78_1
e_1_2_14_236_1
e_1_2_14_224_1
e_1_2_14_29_1
e_1_2_14_201_1
e_1_2_14_141_1
e_1_2_14_164_1
e_1_2_14_187_1
e_1_2_14_9_1
e_1_2_14_126_1
e_1_2_14_149_1
e_1_2_14_102_1
e_1_2_14_82_1
e_1_2_14_67_1
e_1_2_14_273_1
e_1_2_14_21_1
e_1_2_14_44_1
e_1_2_14_209_1
Bucknor MD (e_1_2_14_93_1) 2013; 7
e_1_2_14_247_1
e_1_2_14_190_1
e_1_2_14_18_1
e_1_2_14_235_1
e_1_2_14_212_1
cr-split#-e_1_2_14_156_1.1
cr-split#-e_1_2_14_156_1.2
e_1_2_14_250_1
e_1_2_14_152_1
e_1_2_14_175_1
e_1_2_14_198_1
e_1_2_14_307_1
References_xml – volume: 85
  start-page: 266
  year: 2019
  end-page: 9
  article-title: Successful and safe long‐term treatment of cerebral aspergillosis with high‐dose voriconazole guided by therapeutic drug monitoring
  publication-title: Br J Clin Pharmacol
– volume: 62
  year: 2018
  article-title: Posaconazole‐induced pseudohyperaldosteronism
  publication-title: Antimicrob Agents Chemother
– volume: 44
  start-page: 269
  year: 2009
  end-page: 70
  article-title: Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis
  publication-title: Bone Marrow Transplant
– volume: 2010
  start-page: 351084
  year: 2010
  article-title: Multifocal aggressive squamous cell carcinomas induced by prolonged voriconazole therapy: a case report
  publication-title: Case Rep Med
– volume: 58
  start-page: 432
  year: 2015
  end-page: 6
  article-title: Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis
  publication-title: Mycoses
– volume: 55
  start-page: 24
  year: 2017
  end-page: 6
  article-title: Cerebral rhizomucor infection treated by posaconazole delayed‐release tablets in an allogeneic stem cell transplant recipient
  publication-title: Int J Infect Dis
– volume: 3
  start-page: 143
  year: 1997
  end-page: 4
  article-title: Intravenous penetration of fluconazole during endophthalmitis
  publication-title: Clin Microbiol Infect
– volume: 84
  start-page: 2544
  year: 2018
  end-page: 50
  article-title: Co‐administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed‐released tablets in adult patients with haematological malignancies
  publication-title: Br J Clin Pharmacol
– volume: 55
  start-page: 58
  year: 2012
  end-page: 64
  article-title: Safety of micafungin in prospective and retrospective clinical trials
  publication-title: Mycoses
– volume: 103
  start-page: 1527
  year: 2004
  end-page: 33
  article-title: Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants
  publication-title: Blood
– volume: 71
  start-page: 718
  year: 2016
  end-page: 26
  article-title: Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease
  publication-title: J Antimicrob Chemother
– volume: 72
  start-page: 3406
  year: 2017
  end-page: 13
  article-title: Pharmacokinetics and safety results from the phase 3 randomized, open‐label, study of intravenous posaconazole in patients at risk of invasive fungal disease
  publication-title: J Antimicrob Chemother
– volume: 71
  start-page: 1786
  year: 2016
  end-page: 99
  article-title: Utility of voriconazole therapeutic drug monitoring: a meta‐analysis
  publication-title: J Antimicrob Chemother
– volume: 55
  start-page: 4782
  year: 2011
  end-page: 8
  article-title: Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients
  publication-title: Antimicrob Agents Chemother
– volume: 356
  start-page: 335
  year: 2007
  end-page: 47
  article-title: Posaconazole or fluconazole for prophylaxis in severe graft‐versus‐host disease
  publication-title: N Engl J Med
– volume: 24
  start-page: e1
  year: 2018
  end-page: e38
  article-title: Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID‐ECMM‐ERS guideline
  publication-title: Clin Microbiol Infect
– volume: 70
  start-page: 1161
  year: 2015
  end-page: 5
  article-title: Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole‐treated haematology cohort
  publication-title: J Antimicrob Chemother
– volume: 44
  start-page: 2
  year: 2007
  end-page: 12
  article-title: Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial
  publication-title: Clin Infect Dis
– volume: 80
  start-page: 671
  year: 2020
  end-page: 95
  article-title: Pharmacokinetics and pharmacodynamics of posaconazole
  publication-title: Drugs
– volume: 83
  start-page: 236
  year: 1987
  end-page: 42
  article-title: Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis
  publication-title: Am J Med
– volume: 146
  start-page: 300
  year: 2010
  end-page: 4
  article-title: Melanoma associated with long‐term voriconazole therapy: a new manifestation of chronic photosensitivity
  publication-title: Arch Dermatol
– volume: 2
  start-page: 55
  year: 2015
  end-page: 66
  article-title: Antifungal drug therapeutic monitoring: what are the issues?
  publication-title: Curr Clin Microbiol Rep
– volume: 21
  start-page: 580
  year: 2008
  end-page: 6
  article-title: Therapeutic drug monitoring for triazoles
  publication-title: Curr Opin Infect Dis
– volume: 56
  start-page: 2806
  year: 2012
  end-page: 13
  article-title: Posaconazole exposure‐response relationship: evaluating the utility of therapeutic drug monitoring
  publication-title: Antimicrob Agents Chemother
– volume: 38
  start-page: 241
  year: 2013
  end-page: 2
  article-title: A severe case of haemodynamic instability during anidulafungin administration
  publication-title: J Clin Pharm Ther
– volume: 46
  start-page: 147
  year: 1994
  end-page: 50
  article-title: Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole
  publication-title: Eur J Clin Pharmacol
– volume: 45
  start-page: 1227
  year: 2010
  end-page: 33
  article-title: Caspofungin first‐line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study
  publication-title: Bone Marrow Transplant
– volume: 32a
  start-page: 814
  year: 1996
  end-page: 20
  article-title: Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial
  publication-title: Eur J Cancer
– volume: 62
  start-page: e0260
  year: 2018
  end-page: 17
  article-title: Refractory hypokalemia from syndrome of apparent mineralocorticoid excess on low‐dose posaconazole
  publication-title: Antimicrob Agents Chemother
– volume: 56
  start-page: 2652
  year: 2012
  end-page: 8
  article-title: Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection
  publication-title: Antimicrob Agents Chemother
– volume: 60
  start-page: 6872
  year: 2016
  end-page: 9
  article-title: Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin
  publication-title: Antimicrob Agents Chemother
– volume: 15
  start-page: 589
  year: 2019
  end-page: 95
  article-title: Pharmacokinetic/pharmacodynamic study of posaconazole delayed‐release tablet in a patient with coexisting invasive aspergillosis and mucormycosis
  publication-title: Ther Clin Risk Manag
– volume: 98
  start-page: 711
  year: 1997
  end-page: 18
  article-title: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
  publication-title: Br J Haematol
– volume: 347
  start-page: 2020
  year: 2002
  end-page: 9
  article-title: Comparison of caspofungin and amphotericin B for invasive candidiasis
  publication-title: N Engl J Med
– volume: 38
  start-page: 804
  year: 2016
  end-page: 7
  article-title: Posaconazole therapeutic drug monitoring in a regional hospital setting
  publication-title: Ther Drug Monit
– volume: 10
  start-page: 679
  year: 2010
  article-title: Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method
  publication-title: BMC Cancer
– volume: 56
  start-page: 17
  year: 2003
  end-page: 23
  article-title: Effect of food on the pharmacokinetics of multiple‐dose oral voriconazole
  publication-title: Br J Clin Pharmacol
– volume: 120
  start-page: 2390
  year: 2012
  end-page: 4
  article-title: Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole
  publication-title: Blood
– volume: 48
  start-page: 815
  year: 2004
  end-page: 23
  article-title: Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma
  publication-title: Antimicrob Agents Chemother
– volume: 57
  start-page: 572
  year: 2014
  end-page: 6
  article-title: Disseminated scedosporium prolificans infection in an 'extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics
  publication-title: Mycoses
– volume: 59
  start-page: 3385
  year: 2015
  end-page: 9
  article-title: Effect of a high‐fat meal on the pharmacokinetics of 300‐milligram posaconazole in a solid oral tablet formulation
  publication-title: Antimicrob Agents Chemother
– volume: 33
  start-page: 579
  year: 2013
  end-page: 81
  article-title: Intraocular penetration of itraconazole in patient with fungal endophthalmitis
  publication-title: Int Ophthalmol
– volume: 43
  start-page: 1955
  year: 1999
  end-page: 60
  article-title: Safety and tolerability of fluconazole in children
  publication-title: Antimicrob Agents Chemother
– volume: 44
  start-page: 1364
  year: 2014
  end-page: 88
  article-title: Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014
  publication-title: Intern Med J
– volume: 75
  start-page: 1006
  year: 2020
  end-page: 13
  article-title: Implications for IV posaconazole dosing in the era of obesity
  publication-title: J Antimicrob Chemother
– volume: 32
  start-page: 267
  year: 2004
  end-page: 71
  article-title: Identification of human UDP‐glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil)
  publication-title: Drug Metab Dispos
– volume: 101
  start-page: 170
  year: 1996
  end-page: 6
  article-title: Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study
  publication-title: Am J Med
– volume: 65
  start-page: 410
  year: 2010
  end-page: 16
  article-title: Safety of triazole antifungal drugs in patients with cancer
  publication-title: J Antimicrob Chemother
– volume: 63
  start-page: e00484
  year: 2019
  end-page: 19
  article-title: Treatment by posaconazole tablets, compared to posaconazole suspension, does not reduce variability of posaconazole trough concentrations
  publication-title: Antimicrob Agents Chemother
– volume: 11
  start-page: 75
  year: 2017
  end-page: 83
  article-title: Update on therapeutic drug monitoring of antifungals for the prophylaxis and treatment of invasive fungal infections
  publication-title: Curr Fungal Infect Rep
– volume: 34
  start-page: 13
  year: 2004
  end-page: 20
  article-title: Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections
  publication-title: Bone Marrow Transplant
– volume: 7
  start-page: 1431
  year: 2011
  end-page: 40
  article-title: Pharmacokinetic evaluation of fluconazole in critically ill patients
  publication-title: Expert Opin Drug Metab Toxicol
– volume: 15
  start-page: 1065
  year: 2014
  end-page: 78
  article-title: Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes
  publication-title: Pharmacogenomics
– volume: 53
  start-page: 1712
  year: 2009
  end-page: 14
  article-title: Accelerated metabolism of voriconazole and its partial reversal by cimetidine
  publication-title: Antimicrob Agents Chemother
– volume: 59
  start-page: 726
  year: 2016
  end-page: 33
  article-title: Utilization of posaconazole oral suspension or delayed‐released tablet salvage treatment for invasive fungal infection
  publication-title: Mycoses
– volume: 61
  start-page: 337
  year: 2018
  end-page: 9
  article-title: Itraconazole induced hypertension and hypokalemia: mechanistic evaluation
  publication-title: Mycoses
– volume: 53
  start-page: 958
  year: 2009
  end-page: 66
  article-title: Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers
  publication-title: Antimicrob Agents Chemother
– volume: 60
  start-page: 6945
  year: 2016
  end-page: 7
  article-title: Posaconazole tablet formulation at 400 milligrams daily achieves desired minimum serum concentrations in adult patients with a hematologic malignancy or stem cell transplant
  publication-title: Antimicrob Agents Chemother
– volume: 72
  start-page: 3414
  year: 2017
  end-page: 19
  article-title: Serum levels, safety and tolerability of new formulation SUBA‐itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation
  publication-title: J Antimicrob Chemother
– volume: 108
  start-page: 282
  year: 2000
  end-page: 9
  article-title: A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer
  publication-title: Am J Med
– volume: 56
  start-page: 4793
  year: 2012
  end-page: 9
  article-title: Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring
  publication-title: Antimicrob Agents Chemother
– volume: 52
  start-page: 604
  year: 2011
  end-page: 11
  article-title: Fluoride excess and periostitis in transplant patients receiving long‐term voriconazole therapy
  publication-title: Clin Infect Dis
– volume: 70
  start-page: 2593
  year: 2019
  end-page: 8
  article-title: Posaconazole serum drug levels associated with pseudohyperaldosteronism
  publication-title: Clin Infect Dis
– volume: 17
  start-page: 37
  year: 2014
  end-page: 50
  article-title: The role of azoles in the management of azole‐resistant aspergillosis: from the bench to the bedside
  publication-title: Drug Resist Updat
– volume: 62
  start-page: 1468
  year: 2008
  end-page: 70
  article-title: Posaconazole concentrations in the central nervous system
  publication-title: J Antimicrob Chemother
– volume: 41
  start-page: 755
  year: 2007
  end-page: 63
  article-title: Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database
  publication-title: Ann Pharmacother
– volume: 53
  start-page: 337
  year: 2006
  end-page: 49
  article-title: Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis
  publication-title: J Infect
– volume: 84
  start-page: 1989
  year: 2018
  end-page: 99
  article-title: Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open‐label clinical trial
  publication-title: Br J Clin Pharmacol
– volume: 32
  start-page: 661
  year: 2010
  end-page: 4
  article-title: Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory
  publication-title: Ther Drug Monit
– volume: 11
  start-page: 244
  year: 1977
  end-page: 7
  article-title: Bone marrow toxicity associated with 5‐fluorocytosine therapy
  publication-title: Antimicrob Agents Chemother
– volume: 20
  start-page: 755
  year: 1995
  end-page: 61
  article-title: Pretreatment regimens for adverse events related to infusion of amphotericin B
  publication-title: Clin Infect Dis
– volume: 47
  start-page: 3165
  year: 2003
  end-page: 9
  article-title: In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model
  publication-title: Antimicrob Agents Chemother
– volume: 42
  start-page: 1738
  year: 1998
  end-page: 44
  article-title: P‐glycoprotein‐mediated transport of itraconazole across the blood‐brain barrier
  publication-title: Antimicrob Agents Chemother
– volume: 31
  start-page: 6
  year: 1987
  end-page: 10
  article-title: Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis
  publication-title: Antimicrob Agents Chemother
– volume: 46
  start-page: 201
  year: 2008
  end-page: 11
  article-title: Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
  publication-title: Clin Infect Dis
– volume: 55
  start-page: 1308
  year: 2011
  end-page: 11
  article-title: Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy
  publication-title: Antimicrob Agents Chemother
– volume: 10
  start-page: 341
  year: 1990
  end-page: 8
  article-title: Prospective surveillance of intravenous amphotericin B use patterns
  publication-title: Pharmacotherapy
– volume: 58
  start-page: 53
  year: 2019
  end-page: 61
  article-title: Clinical pharmacokinetics and dose recommendations for posaconazole in infants and children
  publication-title: Clin Pharmacokinet
– volume: 47
  start-page: 477
  year: 2017
  end-page: 82
  article-title: Pharmacist‐led therapeutic drug monitoring: implementation of a successful credentialing model
  publication-title: J Pharm Pract Res
– volume: 41
  start-page: 2714
  year: 1997
  end-page: 18
  article-title: Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units
  publication-title: Antimicrob Agents Chemother
– volume: 88
  start-page: 115
  year: 2010
  end-page: 19
  article-title: Exposure‐response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma
  publication-title: Clin Pharmacol Ther
– volume: 36
  start-page: 213
  year: 2017
  end-page: 17
  article-title: Clinical effectiveness of itraconazole as antifungal prophylaxis in AML patients undergoing intensive chemotherapy in the modern era
  publication-title: Eur J Clin Microbiol Infect Dis
– volume: 45
  start-page: 883
  year: 2007
  end-page: 93
  article-title: Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis
  publication-title: Clin Infect Dis
– volume: 37
  start-page: 766
  year: 2015
  end-page: 71
  article-title: Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease
  publication-title: Ther Drug Monit
– volume: 59
  start-page: 4914
  year: 2015
  end-page: 18
  article-title: Retrospective comparison of posaconazole levels in patients taking the delayed‐release tablet versus the oral suspension
  publication-title: Antimicrob Agents Chemother
– volume: 42
  start-page: 1726
  year: 2006
  end-page: 34
  article-title: Safety of long‐term oral posaconazole use in the treatment of refractory invasive fungal infections
  publication-title: Clin Infect Dis
– volume: 15
  start-page: 881
  year: 2019
  end-page: 95
  article-title: Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients
  publication-title: Expert Opin Drug Metab Toxicol
– volume: 7
  start-page: 10
  year: 2013
  end-page: 17
  article-title: Voriconazole‐induced periostitis in two post‐transplant patients
  publication-title: J Radiol Case Rep
– volume: 56
  start-page: 106180
  year: 2020
  article-title: Therapeutic drug monitoring of commonly used anti‐infective agents: a nationwide cross‐sectional survey of Australian hospital practices
  publication-title: Int J Antimicrob Agents
– volume: 101
  start-page: 782
  year: 2017
  end-page: 90
  article-title: QT interval shortening with isavuconazole: in vitro and in vivo effects on cardiac repolarization
  publication-title: Clin Pharmacol Ther
– volume: 47
  start-page: 2788
  year: 2003
  end-page: 95
  article-title: Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults
  publication-title: Antimicrob Agents Chemother
– volume: 51
  start-page: 3599
  year: 2007
  end-page: 604
  article-title: Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia
  publication-title: Antimicrob Agents Chemother
– volume: 42
  start-page: 443
  year: 1999
  end-page: 51
  article-title: Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole
  publication-title: Mycoses
– volume: 27
  start-page: 296
  year: 1998
  end-page: 302
  article-title: Randomized, double‐blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia
  publication-title: Clin Infect Dis
– volume: 95
  start-page: 337
  year: 2016
  end-page: 44
  article-title: Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study
  publication-title: Ann Hematol
– volume: 63
  start-page: 122
  year: 2020
  end-page: 30
  article-title: High‐dose posaconazole for azole‐resistant aspergillosis and other difficult‐to‐treat mould infections
  publication-title: Mycoses
– volume: 62
  start-page: e01194
  year: 2018
  end-page: 17
  article-title: Pharmacokinetic modeling of voriconazole to develop an alternative dosing regimen in children
  publication-title: Antimicrob Agents Chemother
– volume: 25
  start-page: 47
  year: 2020
  end-page: 52
  article-title: Comparison of the efficacy of posaconazole delayed release tablets and suspension in pediatric hematology/oncology patients
  publication-title: J Pediatr Pharmacol Ther
– volume: 62
  start-page: 698
  year: 2019
  end-page: 705
  article-title: Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations
  publication-title: Mycoses
– volume: 61
  start-page: 256
  year: 2018
  end-page: 60
  article-title: Isavuconazole shortens the QTc interval
  publication-title: Mycoses
– volume: 16
  start-page: 927
  year: 2010
  end-page: 33
  article-title: Voriconazole concentrations and outcome of invasive fungal infections
  publication-title: Clin Microbiol Infect
– volume: 36
  start-page: 1122
  year: 2003
  end-page: 231
  article-title: Voriconazole treatment for less‐common, emerging, or refractory fungal infections
  publication-title: Clin Infect Dis
– volume: 2
  start-page: 98
  year: 2013
  end-page: 102
  article-title: Locally extensive angio‐invasive scedosporium prolificans infection following resection for squamous cell lung carcinoma
  publication-title: Med Mycol Case Rep
– volume: 24
  start-page: 63
  year: 2018
  end-page: 6
  article-title: Failure to achieve therapeutic levels with high‐dose posaconazole tablets potentially due to enhanced clearance
  publication-title: J Oncol Pharm Pract
– volume: 65
  start-page: 107
  year: 2010
  end-page: 13
  article-title: Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients
  publication-title: J Antimicrob Chemother
– volume: 57
  start-page: 527
  year: 2006
  end-page: 35
  article-title: Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey
  publication-title: J Antimicrob Chemother
– volume: 14
  start-page: 270
  year: 1978
  end-page: 3
  article-title: Erythropoietin concentration in amphotericin B‐induced anemia
  publication-title: Antimicrob Agents Chemother
– volume: 18
  start-page: 2227
  year: 2003
  end-page: 31
  article-title: Dosing guidelines for fluconazole in patients with renal failure
  publication-title: Nephrol Dial Transplant
– volume: 37
  start-page: 728
  year: 2003
  end-page: 32
  article-title: Voriconazole concentrations in the cerebrospinal fluid and brain tissue of Guinea pigs and immunocompromised patients
  publication-title: Clin Infect Dis
– volume: 39
  start-page: 1563
  year: 2004
  end-page: 71
  article-title: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy
  publication-title: Clin Infect Dis
– volume: 28
  start-page: 250
  year: 1999
  end-page: 5
  article-title: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo‐controlled, double‐blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto
  publication-title: Clin Infect Dis
– volume: 49
  start-page: 1331
  year: 2005
  end-page: 6
  article-title: Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant
  publication-title: Antimicrob Agents Chemother
– volume: 37
  start-page: 1270
  year: 1993
  end-page: 7
  article-title: Pharmacokinetics of 18F‐labeled fluconazole in healthy human subjects by positron emission tomography
  publication-title: Antimicrob Agents Chemother
– volume: 21
  start-page: 4615
  year: 2003
  end-page: 26
  article-title: Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta‐analysis of 3,597 patients
  publication-title: J Clin Oncol
– volume: 46
  start-page: 171
  year: 2000
  end-page: 9
  article-title: Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions
  publication-title: J Antimicrob Chemother
– volume: 54
  start-page: 4074
  year: 2010
  end-page: 7
  article-title: Antifungal therapy in a murine model of disseminated infection by cryptococcus gattii
  publication-title: Antimicrob Agents Chemother
– volume: 57
  start-page: 2793
  year: 2013
  end-page: 800
  article-title: Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints
  publication-title: Antimicrob Agents Chemother
– volume: 69
  start-page: 95
  year: 2009
  end-page: 7
  article-title: Anidulafungin, a new echinocandin: effectiveness and tolerability
  publication-title: Drugs
– volume: 15
  start-page: 651
  year: 2014
  end-page: 79
  article-title: Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450
  publication-title: Curr Drug Metab
– volume: 62
  start-page: e02655
  year: 2018
  end-page: 17
  article-title: Antifungal prophylaxis with posaconazole delayed‐release tablet and oral suspension in a real‐life setting: plasma levels, efficacy, and tolerability
  publication-title: Antimicrob Agents Chemother
– volume: 72
  start-page: 342
  year: 2004
  end-page: 7
  article-title: Low‐dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies – a randomized, controlled trial
  publication-title: Eur J Haematol
– volume: 62
  start-page: e00705
  year: 2018
  end-page: 18
  article-title: Is it time for systematic voriconazole pharmacogenomic investigation for central nervous system aspergillosis?
  publication-title: Antimicrob Agents Chemother
– volume: 18
  start-page: 295
  year: 1998
  end-page: 301
  article-title: Food interaction and steady‐state pharmacokinetics of itraconazole oral solution in healthy volunteers
  publication-title: Pharmacotherapy
– volume: 24
  year: 2020
  article-title: Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole
  publication-title: Pediatr Transplant
– volume: 186
  start-page: 379
  year: 2002
  end-page: 88
  article-title: Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study
  publication-title: J Infect Dis
– volume: 107
  start-page: 916
  year: 2006
  end-page: 23
  article-title: Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH‐mediated repression of HIF‐1
  publication-title: Blood
– volume: 50
  start-page: 477
  year: 1997
  end-page: 80
  article-title: Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis
  publication-title: J Clin Pathol
– volume: 31
  start-page: 490
  year: 2018
  end-page: 8
  article-title: Antifungal stewardship: developments in the field
  publication-title: Curr Opin Infect Dis
– volume: 40
  start-page: 1456
  year: 2006
  end-page: 61
  article-title: Long QTc interval and torsade de pointes caused by fluconazole
  publication-title: Ann Pharmacother
– volume: 97
  start-page: 135
  year: 1994
  end-page: 44
  article-title: NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis
  publication-title: Am J Med
– volume: 15
  start-page: 1003
  year: 1992
  end-page: 18
  article-title: Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy
  publication-title: Clin Infect Dis
– volume: 17
  start-page: 691
  year: 1978
  end-page: 4
  article-title: Ocular penetration of 5‐fluorocytosine
  publication-title: Invest Ophthalmol Vis Sci
– volume: 53
  start-page: 1793
  year: 2009
  end-page: 6
  article-title: Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation
  publication-title: Antimicrob Agents Chemother
– volume: 9
  start-page: 89
  year: 2017
  end-page: 91
  article-title: A suspected case of autoinduction of voriconazole metabolism in a patient with cerebral aspergillosis
  publication-title: Drug Healthc Patient Saf
– volume: 71
  start-page: 285
  year: 2016
  end-page: 9
  article-title: Antifungal therapy: drug‐drug interactions at your fingertips
  publication-title: J Antimicrob Chemother
– volume: 356
  start-page: 348
  year: 2007
  end-page: 59
  article-title: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
  publication-title: N Engl J Med
– volume: 50
  start-page: 632
  year: 2006
  end-page: 8
  article-title: Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections
  publication-title: Antimicrob Agents Chemother
– volume: 92
  start-page: 871
  year: 2008
  end-page: 8
  article-title: Voriconazole in the treatment of fungal eye infections: a review of current literature
  publication-title: Br J Ophthalmol
– volume: 35
  start-page: 359
  year: 2002
  end-page: 66
  article-title: A double‐blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients
  publication-title: Clin Infect Dis
– volume: 36
  start-page: 1221
  year: 2003
  end-page: 8
  article-title: A randomized and blinded multicenter trial of high‐dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects
  publication-title: Clin Infect Dis
– volume: 13
  start-page: 5
  year: 2014
  end-page: 14
  article-title: Cardiac toxicity of some echinocandin antifungals
  publication-title: Expert Opin Drug Saf
– volume: 55
  start-page: 667
  year: 1979
  end-page: 70
  article-title: Pharmacokinetics of amphotericin B and flucytosine
  publication-title: Postgrad Med J
– volume: 72
  start-page: 2902
  year: 2017
  end-page: 5
  article-title: Risk factors for subtherapeutic levels of posaconazole tablet
  publication-title: J Antimicrob Chemother
– volume: 31
  start-page: 1155
  year: 2000
  end-page: 63
  article-title: A randomized, double‐blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group
  publication-title: Clin Infect Dis
– volume: 3
  start-page: 1361
  year: 2019
  end-page: 6
  article-title: Posaconazole‐induced hypertension due to inhibition of 11β‐hydroxylase and 11β‐hydroxysteroid dehydrogenase 2
  publication-title: J Endocr Soc
– volume: 72
  start-page: 2355
  year: 2017
  end-page: 8
  article-title: Multicentre study of posaconazole delayed‐release tablet serum level and association with hepatotoxicity and QTc prolongation
  publication-title: J Antimicrob Chemother
– volume: 63
  start-page: e1
  year: 2016
  end-page: e60
  article-title: Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America
  publication-title: Clin Infect Dis
– volume: 57
  start-page: 5271
  year: 2013
  end-page: 6
  article-title: Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy
  publication-title: Antimicrob Agents Chemother
– volume: 55
  start-page: 925
  year: 2011
  end-page: 8
  article-title: Human tissue distribution of voriconazole
  publication-title: Antimicrob Agents Chemother
– volume: 346
  start-page: 225
  year: 2002
  end-page: 34
  article-title: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
  publication-title: N Engl J Med
– volume: 2015
  start-page: 927496
  year: 2015
  article-title: Flucytosine pharmacokinetics in a critically ill patient receiving continuous renal replacement therapy
  publication-title: Case Rep Crit Care
– volume: 49
  start-page: 3171
  year: 2005
  end-page: 7
  article-title: Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia
  publication-title: Antimicrob Agents Chemother
– volume: 86
  start-page: 829
  year: 2002
  end-page: 30
  article-title: Ocular and systemic posaconazole (SCH‐56592) treatment of invasive fusarium solani keratitis and endophthalmitis
  publication-title: Br J Ophthalmol
– volume: 35
  start-page: 707
  year: 1991
  end-page: 13
  article-title: High‐dose itraconazole in the treatment of severe mycoses
  publication-title: Antimicrob Agents Chemother
– volume: 35
  start-page: 797
  year: 2015
  end-page: 804
  article-title: Pharmacokinetic and pharmacodynamic properties of oral voriconazole in patients with invasive fungal infections
  publication-title: Pharmacotherapy
– volume: 4
  start-page: 25
  year: 2002
  end-page: 30
  article-title: Safety and tolerability of caspofungin acetate in the treatment of fungal infections
  publication-title: Transpl Infect Dis
– volume: 63
  start-page: e02353
  year: 2019
  end-page: 18
  article-title: Software for dosage individualization of voriconazole: a prospective clinical study
  publication-title: Antimicrob Agents Chemother
– volume: 56
  start-page: 5503
  year: 2012
  end-page: 10
  article-title: Multicenter study of posaconazole therapeutic drug monitoring: exposure‐response relationship and factors affecting concentration
  publication-title: Antimicrob Agents Chemother
– volume: 10
  start-page: 51
  year: 2016
  end-page: 61
  article-title: Therapeutic drug monitoring of posaconazole: an update
  publication-title: Curr Fungal Infect Rep
– volume: 44
  start-page: e55
  year: 2007
  end-page: 6
  article-title: Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy
  publication-title: Clin Infect Dis
– volume: 340
  start-page: 764
  year: 1999
  end-page: 71
  article-title: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group
  publication-title: N Engl J Med
– volume: 32
  start-page: 538
  year: 2019
  end-page: 45
  article-title: Azole antifungals and new targeted therapies for hematological malignancy
  publication-title: Curr Opin Infect Dis
– volume: 36
  start-page: 242
  year: 2011
  end-page: 4
  article-title: A case of periostitis secondary to voriconazole therapy in a heart transplant recipient
  publication-title: Clin Nucl Med
– volume: 25
  start-page: 1305
  year: 2019
  end-page: 11
  article-title: Evaluating a voriconazole dose modification guideline to optimize dosing in patients with hematologic malignancies
  publication-title: J Oncol Pharm Pract
– volume: 25
  start-page: 605
  year: 2012
  end-page: 11
  article-title: Making sense of posaconazole therapeutic drug monitoring: a practical approach
  publication-title: Curr Opin Infect Dis
– volume: 34
  start-page: 118
  year: 2012
  end-page: 89
  article-title: Posaconazole serum level on day 2 predicts steady state posaconazole serum level
  publication-title: Ther Drug Monit
– volume: 73
  start-page: 134
  year: 2018
  end-page: 42
  article-title: Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs
  publication-title: J Antimicrob Chemother
– volume: 71
  start-page: 2234
  year: 2016
  end-page: 40
  article-title: Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial
  publication-title: J Antimicrob Chemother
– volume: 28
  start-page: 648
  year: 1985
  end-page: 53
  article-title: Pharmacokinetic evaluation of UK‐49,858, a metabolically stable triazole antifungal drug, in animals and humans
  publication-title: Antimicrob Agents Chemother
– volume: 6
  start-page: 110
  year: 2004
  end-page: 16
  article-title: Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A
  publication-title: Transpl Infect Dis
– volume: 16
  start-page: 828
  year: 2016
  end-page: 37
  article-title: Isavuconazole treatment for mucormycosis: a single‐arm open‐label trial and case‐control analysis
  publication-title: Lancet Infect Dis
– volume: 62
  start-page: e00885
  year: 2018
  end-page: 18
  article-title: Population pharmacokinetics and cerebrospinal fluid penetration of fluconazole in adults with cryptococcal meningitis
  publication-title: Antimicrob Agents Chemother
– volume: 65
  start-page: 281
  year: 2009
  end-page: 5
  article-title: The CYP2C19 ultra‐rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers
  publication-title: Eur J Clin Pharmacol
– volume: 61
  start-page: e01034
  year: 2017
  end-page: 17
  article-title: Exposure‐response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi
  publication-title: Antimicrob Agents Chemother
– volume: 32
  start-page: 387
  year: 2013
  end-page: 97
  article-title: A double‐blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis
  publication-title: Eur J Clin Microbiol Infect Dis
– volume: 27
  start-page: 68
  year: 2014
  end-page: 88
  article-title: Tissue penetration of antifungal agents
  publication-title: Clin Microbiol Rev
– volume: 37
  start-page: 508
  year: 2015
  end-page: 11
  article-title: Therapeutic drug monitoring and dose adjustment of posaconazole oral suspension in adults with acute myeloid leukemia
  publication-title: Ther Drug Monit
– start-page: 2919
  year: 2017
  end-page: 26
– volume: 18
  start-page: 1509
  year: 2012
  end-page: 16
  article-title: Multicenter, randomized, open‐label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant
  publication-title: Biol Blood Marrow Transplant
– volume: 73
  start-page: i33
  year: 2018
  end-page: 43
  article-title: Overview of antifungal dosing in invasive candidiasis
  publication-title: J Antimicrob Chemother
– volume: 33
  start-page: 1529
  year: 2001
  end-page: 35
  article-title: A randomized double‐blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis
  publication-title: Clin Infect Dis
– volume: 61
  start-page: 17
  year: 2008
  end-page: 25
  article-title: Antifungal serum concentration monitoring: an update
  publication-title: J Antimicrob Chemother
– volume: 59
  start-page: 818
  year: 2007
  end-page: 19
  article-title: Voriconazole concentrations in synovial fluid and bone tissues
  publication-title: J Antimicrob Chemother
– volume: 32
  start-page: 1310
  year: 1988
  end-page: 13
  article-title: Pharmacokinetics of itraconazole following oral administration to normal volunteers
  publication-title: Antimicrob Agents Chemother
– volume: 29
  start-page: 1402
  year: 1999
  end-page: 7
  article-title: Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis
  publication-title: Clin Infect Dis
– volume: 32
  start-page: 321
  year: 2007
  end-page: 4
  article-title: Inherited long QT syndrome revealed by antifungals drug‐drug interaction
  publication-title: J Clin Pharm Ther
– volume: 322
  start-page: 579
  year: 2001
  end-page: 82
  article-title: Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial
  publication-title: BMJ
– volume: 8
  start-page: 60
  year: 2019
  end-page: 9
  article-title: Clinical pharmacokinetics and drug‐drug interaction potential for coadministered SCY‐078, an oral fungicidal glucan synthase inhibitor, and tacrolimus
  publication-title: Clin Pharmacol Drug Dev
– volume: 49
  start-page: 928
  year: 2009
  end-page: 30
  article-title: Toxicodynamics of itraconazole: implications for therapeutic drug monitoring
  publication-title: Clin Infect Dis
– volume: 138
  start-page: 705
  year: 2003
  end-page: 13
  article-title: Intravenous and oral itraconazole versus intravenous and oral fluconazole for long‐term antifungal prophylaxis in allogeneic hematopoietic stem‐cell transplant recipients. A multicenter, randomized trial
  publication-title: Ann Intern Med
– volume: 59
  start-page: 1527
  year: 2014
  end-page: 33
  article-title: Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically ill children
  publication-title: Clin Infect Dis
– volume: 105
  start-page: 901
  year: 1999
  end-page: 11
  article-title: A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group
  publication-title: Br J Haematol
– volume: 48
  start-page: 1472
  year: 2013
  end-page: 7
  article-title: Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo‐identical hematopoietic SCT
  publication-title: Bone Marrow Transplant
– volume: 9
  start-page: 2845
  year: 2009
  end-page: 50
  article-title: Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients
  publication-title: Am J Transplant
– volume: 71
  start-page: 2062
  year: 2016
  article-title: Comment on: antifungal therapy: drug‐drug interactions at your fingertips
  publication-title: J Antimicrob Chemother
– volume: 61
  start-page: e00760
  year: 2017
  end-page: 17
  article-title: In vivo 11β‐hydroxysteroid dehydrogenase inhibition in posaconazole‐induced hypertension and hypokalemia
  publication-title: Antimicrob Agents Chemother
– volume: 21
  start-page: 645
  year: 2004
  end-page: 53
  article-title: Effect of posaconazole on cytochrome P450 enzymes: a randomized, open‐label, two‐way crossover study
  publication-title: Eur J Pharm Sci
– volume: 14
  start-page: 731
  year: 2016
  end-page: 46
  article-title: Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections
  publication-title: Expert Rev Anti Infect Ther
– volume: 27
  start-page: 1154
  year: 2004
  end-page: 6
  article-title: Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats
  publication-title: Biol Pharm Bull
– volume: 356
  start-page: 2472
  year: 2007
  end-page: 82
  article-title: Anidulafungin versus fluconazole for invasive candidiasis
  publication-title: N Engl J Med
– volume: 32
  start-page: 369
  year: 1988
  end-page: 73
  article-title: Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis
  publication-title: Antimicrob Agents Chemother
– volume: 51
  start-page: 18
  year: 2021
  end-page: 36
  article-title: Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021
  publication-title: Internal Medicine Journal
– volume: 19
  start-page: 33
  year: 2015
  article-title: Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients study
  publication-title: Crit Care
– volume: 74
  start-page: 2341
  year: 2019
  end-page: 6
  article-title: Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy
  publication-title: J Antimicrob Chemother
– volume: 21
  start-page: 1239
  year: 1998
  end-page: 43
  article-title: Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation
  publication-title: Bone Marrow Transplant
– start-page: 223
  year: 1987
  end-page: 59
– volume: 17
  start-page: 11
  year: 2017
  end-page: 13
  article-title: Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient
  publication-title: Med Mycol Case Rep
– volume: 69
  start-page: 1162
  year: 2014
  end-page: 76
  article-title: Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
  publication-title: J Antimicrob Chemother
– volume: 366
  start-page: 1435
  year: 2005
  end-page: 42
  article-title: Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non‐neutropenic patients: a randomised non‐inferiority trial
  publication-title: Lancet
– volume: 18
  start-page: 155
  year: 2018
  article-title: Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta‐analysis with trial sequential analysis
  publication-title: BMC Infect Dis
– volume: 63
  start-page: 604
  year: 2020
  end-page: 9
  article-title: Posaconazole delayed‐release tablets in paediatric haematology‐oncology patients
  publication-title: Mycoses
– volume: 44
  start-page: 201
  year: 2019
  end-page: 15
  article-title: Mechanistic assessment of the effect of omeprazole on the in vivo pharmacokinetics of itraconazole in healthy volunteers
  publication-title: Eur J Drug Metab Pharmacokinet
– volume: 72
  start-page: 12
  year: 2017
  end-page: 18
  article-title: Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations
  publication-title: J Antimicrob Chemother
– volume: 59
  start-page: 226
  year: 2016
  end-page: 33
  article-title: Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections
  publication-title: Mycoses
– volume: 71
  start-page: 11
  year: 2011
  end-page: 41
  article-title: Echinocandin antifungal drugs in fungal infections: a comparison
  publication-title: Drugs
– volume: 42
  start-page: 591
  year: 1999
  end-page: 600
  article-title: Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl‐β‐cyclodextrin oral solution or coated‐pellet capsules
  publication-title: Mycoses
– volume: 47
  start-page: e7
  year: 2008
  end-page: e10
  article-title: Hallucinations during voriconazole therapy
  publication-title: Clin Infect Dis
– volume: 70
  start-page: 1221
  year: 2014
  end-page: 6
  article-title: GFR may not accurately predict aspects of proximal tubule drug handling
  publication-title: Eur J Clin Pharmacol
– volume: 30
  start-page: 459
  year: 2016
  end-page: 65
  article-title: Optimization of voriconazole dosage regimen to improve the efficacy in patients with invasive fungal disease by pharmacokinetic/pharmacodynamic analysis
  publication-title: Fundam Clin Pharmacol
– volume: 387
  start-page: 760
  year: 2016
  end-page: 9
  article-title: Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised‐controlled, non‐inferiority trial
  publication-title: Lancet
– volume: 6
  start-page: 2231
  year: 2005
  end-page: 43
  article-title: Drug‐drug interactions of antifungal agents and implications for patient care
  publication-title: Expert Opin Pharmacother
– volume: 347
  start-page: 408
  year: 2002
  end-page: 15
  article-title: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
  publication-title: N Engl J Med
– volume: 54
  start-page: 919
  year: 2010
  end-page: 23
  article-title: Murine model of a disseminated infection by the novel fungus and successful treatment with posaconazole
  publication-title: Antimicrob Agents Chemother
– volume: 55
  start-page: 1080
  year: 2012
  end-page: 7
  article-title: The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial
  publication-title: Clin Infect Dis
– volume: 76
  start-page: 249
  year: 2021
  end-page: 52
  article-title: Clinical experience with SUBA‐itraconazole at a tertiary paediatric hospital
  publication-title: J Antimicrob Chemother
– volume: 3
  start-page: 71
  year: 2007
  end-page: 97
  article-title: Comparison of echinocandin antifungals
  publication-title: Ther Clin Risk Manag
– volume: 1
  start-page: 476
  year: 1972
  end-page: 82
  article-title: Pharmacological studies with 5‐fluorocytosine
  publication-title: Antimicrob Agents Chemother
– volume: 45
  start-page: 2845
  year: 2001
  end-page: 55
  article-title: Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling
  publication-title: Antimicrob Agents Chemother
– volume: 60
  start-page: 5600
  year: 2016
  end-page: 3
  article-title: Isavuconazole is effective for the treatment of experimental cryptococcal meningitis
  publication-title: Antimicrob Agents Chemother
– volume: 48
  start-page: 1441
  year: 2009
  end-page: 58
  article-title: Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents
  publication-title: Clin Infect Dis
– volume: 331
  start-page: 1325
  year: 1994
  end-page: 30
  article-title: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute
  publication-title: N Engl J Med
– volume: 44
  start-page: 1277
  year: 2014
  end-page: 82
  article-title: Survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand
  publication-title: Intern Med J
– volume: 113
  start-page: 294
  year: 2002
  end-page: 9
  article-title: A randomized double‐blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis
  publication-title: Am J Med
– volume: 18
  start-page: 657
  year: 2014
  article-title: Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds
  publication-title: Crit Care
– volume: 63
  start-page: e01435
  year: 2019
  end-page: 19
  article-title: Using state transition models to explore how the prevalence of subtherapeutic posaconazole exposures impacts the clinical utility of therapeutic drug monitoring for posaconazole tablets and oral suspension
  publication-title: Antimicrob Agents Chemother
– start-page: 1806
  year: 2010
  end-page: 23
– volume: 25
  start-page: 327
  year: 2014
  end-page: 43
  article-title: Therapeutic drug monitoring for triazoles: a needs assessment review and recommendations from a Canadian perspective
  publication-title: Can J Infect Dis Med Microbiol
– volume: 44
  start-page: 1009
  year: 2005
  end-page: 34
  article-title: Antimicrobial therapy in critically ill patients
  publication-title: Clin Pharmacokinet
– volume: 298
  start-page: 299
  year: 1989
  end-page: 304
  article-title: Sodium protects against nephrotoxicity in patients receiving amphotericin B
  publication-title: Am J Med Sci
– volume: 73
  start-page: 748
  year: 2018
  end-page: 56
  article-title: Single‐centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations
  publication-title: J Antimicrob Chemother
– volume: 16
  start-page: 60
  year: 2017
  article-title: Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study
  publication-title: Ann Clin Microbiol Antimicrob
– volume: 62
  start-page: 31
  year: 2010
  end-page: 7
  article-title: Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole
  publication-title: J Am Acad Dermatol
– volume: 34
  start-page: 563
  year: 2002
  end-page: 71
  article-title: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
  publication-title: Clin Infect Dis
– volume: 58
  start-page: 5758
  year: 2014
  end-page: 65
  article-title: Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high‐risk patients with neutropenia
  publication-title: Antimicrob Agents Chemother
– volume: 37
  start-page: 491
  year: 2012
  end-page: 3
  article-title: Flash pulmonary oedema during anidulafungin administration
  publication-title: J Clin Pharm Ther
– volume: 46
  start-page: 235
  year: 2006
  end-page: 43
  article-title: Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities
  publication-title: J Clin Pharmacol
– volume: 28
  start-page: 363
  year: 1988
  end-page: 6
  article-title: Fluconazole penetration into cerebrospinal fluid in humans
  publication-title: J Clin Pharmacol
– volume: 50
  start-page: 92
  year: 2009
  end-page: 100
  article-title: Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders
  publication-title: Leuk Lymphoma
– volume: 2
  year: 2015
  article-title: Voriconazole dose modification guideline to optimize therapeutic levels in patients with hematologic malignancies
  publication-title: Open Forum Infect Dis
– volume: 62
  start-page: 214
  year: 2019
  end-page: 16
  article-title: Managing liver dysfunction in haematology patients: switch antifungals, or use the tincture of time?
  publication-title: Mycoses
– volume: 35
  start-page: e20
  year: 2015
  end-page: e6
  article-title: Autoinduction of voriconazole metabolism in a child with invasive pulmonary aspergillosis
  publication-title: Pharmacotherapy
– volume: 68
  start-page: 1981
  year: 2019
  end-page: 9
  article-title: Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: the ACTIVE trial
  publication-title: Clin Infect Dis
– volume: 39
  start-page: 1407
  year: 2004
  end-page: 16
  article-title: Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation
  publication-title: Clin Infect Dis
– volume: 56
  start-page: 526
  year: 2012
  end-page: 31
  article-title: Population pharmacokinetics of voriconazole in adults
  publication-title: Antimicrob Agents Chemother
– volume: 40
  start-page: 302
  year: 1991
  end-page: 8
  article-title: Effect of salt supplementation on amphotericin B nephrotoxicity
  publication-title: Kidney Int
– volume: 3
  year: 2000
  article-title: Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia
  publication-title: Cochrane Database Syst Rev
– volume: 11
  start-page: 691
  year: 2018
  end-page: 3
  article-title: Posaconazole‐induced hypertension and hypokalemia due to inhibition of the 11β‐hydroxylase enzyme
  publication-title: Clin Kidney J
– volume: 24
  start-page: 599
  year: 2018
  end-page: 603
  article-title: Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre‐ and post‐switch to tablet formulation
  publication-title: J Oncol Pharm Pract
– volume: 56
  start-page: 2371
  year: 2012
  end-page: 7
  article-title: Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity
  publication-title: Antimicrob Agents Chemother
– volume: 102
  start-page: 45
  year: 2017
  end-page: 51
  article-title: Clinical Pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy
  publication-title: Clin Pharmacol Ther
– volume: 46
  start-page: 86
  year: 2000
  end-page: 94
  article-title: Flucytosine: correlation between toxicity and pharmacokinetic parameters
  publication-title: Chemotherapy
– volume: 74
  start-page: 3049
  year: 2019
  end-page: 55
  article-title: Clinical experience with new formulation SUBA®‐itraconazole for prophylaxis in patients undergoing stem cell transplantation or treatment for haematological malignancies
  publication-title: J Antimicrob Chemother
– volume: 42
  start-page: 1512
  year: 1998
  end-page: 14
  article-title: Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration‐time curve values which mimic those of high‐dose fluconazole in humans
  publication-title: Antimicrob Agents Chemother
– volume: 50
  start-page: 658
  year: 2006
  end-page: 66
  article-title: Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection
  publication-title: Antimicrob Agents Chemother
– volume: 26
  start-page: 1008
  year: 2020
  end-page: 16
  article-title: How to design a study to evaluate therapeutic drug monitoring in infectious diseases?
  publication-title: Clin Microbiol Infect
– volume: 3
  start-page: 573
  year: 2007
  end-page: 81
  article-title: CNS pharmacokinetics of antifungal agents
  publication-title: Expert Opin Drug Metab Toxicol
– volume: 11
  start-page: 276
  year: 2010
  end-page: 81
  article-title: Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV‐associated cryptococcal meningitis‐infected patients
  publication-title: HIV Med
– volume: 14
  start-page: 257
  year: 2016
  end-page: 67
  article-title: Dosing of antifungal agents in obese people
  publication-title: Expert Rev Anti Infect Ther
– volume: 104
  start-page: 957
  year: 2018
  end-page: 65
  article-title: Optimization of voriconazole therapy for the treatment of invasive fungal infections in adults
  publication-title: Clin Pharmacol Ther
– volume: 62
  start-page: e02516
  year: 2018
  end-page: 17
  article-title: Pharmacodynamics of voriconazole for invasive pulmonary scedosporiosis
  publication-title: Antimicrob Agents Chemother
– volume: 62
  start-page: 1682
  year: 2015
  article-title: Suspected posaconazole toxicity in a pediatric oncology patient
  publication-title: Pediatr Blood Cancer
– volume: 34
  start-page: e793
  year: 2011
  end-page: 6
  article-title: Periostitis secondary to prolonged voriconazole therapy in a lung transplant recipient
  publication-title: Orthopedics
– volume: 56
  start-page: 6001
  year: 2012
  end-page: 2
  article-title: Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections
  publication-title: Antimicrob Agents Chemother
– volume: 49
  start-page: 196
  year: 2009
  end-page: 204
  article-title: CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole
  publication-title: J Clin Pharmacol
– volume: 35
  start-page: e219
  year: 2013
  end-page: 23
  article-title: Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children
  publication-title: J Pediatr Hematol Oncol
– volume: 12
  start-page: 318
  year: 1990
  end-page: 26
  article-title: Pharmacokinetics and tissue penetration of fluconazole in humans
  publication-title: Rev Infect Dis
– volume: 40
  start-page: 451
  year: 2007
  end-page: 6
  article-title: Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole
  publication-title: Bone Marrow Transplant
– volume: 25
  start-page: 703
  year: 2019
  end-page: 5
  article-title: The challenges of treating aspergillus abdominal aneurysm after hematopoietic cell transplant: rapid voriconazole metabolizer
  publication-title: J Oncol Pharm Pract
– volume: 39
  start-page: 770
  year: 2004
  end-page: 5
  article-title: A randomized, double‐blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis
  publication-title: Clin Infect Dis
– volume: 78
  start-page: 409
  year: 2019
  end-page: 21
  article-title: Subtherapeutic posaconazole troughs despite high‐dose posaconazole tablets in a patient with terminal ileum resection
  publication-title: J Infect
– year: 2012
– volume: 369
  start-page: 1519
  year: 2007
  end-page: 27
  article-title: Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double‐blind trial
  publication-title: Lancet
– volume: 62
  start-page: e01723
  year: 2018
  end-page: 18
  article-title: Effects of food and omeprazole on a novel formulation of super bioavailability itraconazole in healthy subjects
  publication-title: Antimicrob Agents Chemother
– volume: 2
  start-page: 114
  year: 1972
  end-page: 21
  article-title: In vitro studies of 5‐fluorocytosine resistance in and
  publication-title: Antimicrob Agents Chemother
– volume: 351
  start-page: 1391
  year: 2004
  end-page: 402
  article-title: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia
  publication-title: N Engl J Med
– volume: 54
  start-page: 207
  year: 2010
  end-page: 12
  article-title: Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation
  publication-title: Antimicrob Agents Chemother
– volume: 135
  start-page: 412
  year: 2001
  end-page: 22
  article-title: Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad‐spectrum antibacterial therapy. A randomized, controlled trial
  publication-title: Ann Intern Med
– volume: 31
  start-page: 214
  year: 2011
  end-page: 25
  article-title: Therapeutic drug monitoring of voriconazole and posaconazole
  publication-title: Pharmacotherapy
– volume: 57
  start-page: 328
  year: 2019
  end-page: 43
  article-title: Antifungal drugs: what brings the future?
  publication-title: Med Mycol
– volume: 38
  start-page: 429
  year: 2013
  end-page: 31
  article-title: Cardiac effects of echinocandin preparations – three case reports
  publication-title: J Clin Pharm Ther
– volume: 60
  start-page: 6550
  year: 2016
  end-page: 7
  article-title: Effect of obesity on the population pharmacokinetics of fluconazole in critically ill patients
  publication-title: Antimicrob Agents Chemother
– volume: 17
  start-page: 73
  year: 2011
  end-page: 5
  article-title: Multifocal nodular periostitis associated with prolonged voriconazole therapy in a lung transplant recipient
  publication-title: J Clin Rheumatol
– volume: 58
  start-page: 362
  year: 2015
  end-page: 7
  article-title: Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections
  publication-title: Mycoses
– volume: 25
  start-page: 138
  year: 2006
  end-page: 49
  article-title: Adverse effects of antifungal therapies in invasive fungal infections: review and meta‐analysis
  publication-title: Eur J Clin Microbiol Infect Dis
– ident: e_1_2_14_30_1
  doi: 10.1016/j.ejps.2004.01.005
– ident: e_1_2_14_300_1
  doi: 10.1002/phar.1566
– ident: e_1_2_14_49_1
  doi: 10.1056/NEJM199903113401004
– ident: e_1_2_14_128_1
  doi: 10.2147/tcrm.2007.3.1.71
– ident: e_1_2_14_175_1
  doi: 10.1097/FTD.0b013e31823cef77
– ident: e_1_2_14_91_1
  doi: 10.1086/524669
– ident: e_1_2_14_180_1
  doi: 10.1128/AAC.01489-16
– ident: e_1_2_14_77_1
  doi: 10.1046/j.1439-0507.1999.00518.x
– ident: e_1_2_14_154_1
  doi: 10.1093/jac/dkm389
– ident: e_1_2_14_227_1
  doi: 10.1128/AAC.02516-17
– ident: e_1_2_14_278_1
  doi: 10.1136/bjo.86.7.829-a
– ident: e_1_2_14_305_1
  doi: 10.1016/j.mmcr.2017.05.004
– ident: e_1_2_14_101_1
  doi: 10.1086/508774
– ident: e_1_2_14_107_1
  doi: 10.1128/AAC.02130-17
– ident: e_1_2_14_197_1
  doi: 10.1016/j.jinf.2019.02.013
– ident: e_1_2_14_193_1
  doi: 10.1111/myc.13084
– ident: e_1_2_14_5_1
  doi: 10.1007/s10096-016-2780-z
– ident: e_1_2_14_192_1
  doi: 10.1111/petr.13777
– ident: e_1_2_14_276_1
  doi: 10.1093/jac/dkn409
– ident: e_1_2_14_304_1
  doi: 10.1128/AAC.01325-10
– ident: e_1_2_14_268_1
  doi: 10.1111/j.1468-1293.2009.00778.x
– ident: e_1_2_14_203_1
  doi: 10.1007/s40588-015-0019-x
– ident: e_1_2_14_155_1
  doi: 10.1128/AAC.2.3.114
– ident: e_1_2_14_269_1
  doi: 10.1111/j.1469-0691.1997.tb00269.x
– ident: e_1_2_14_307_1
  doi: 10.1111/imj.15586
– ident: e_1_2_14_188_1
  doi: 10.1093/jac/dkx440
– ident: e_1_2_14_113_1
  doi: 10.1093/cid/ciy827
– ident: e_1_2_14_229_1
  doi: 10.1093/jac/dkw127
– ident: e_1_2_14_242_1
  doi: 10.1007/s00228-008-0574-7
– ident: e_1_2_14_70_1
  doi: 10.1086/374850
– ident: e_1_2_14_134_1
  doi: 10.2165/11315570-000000000-00000
– ident: e_1_2_14_86_1
  doi: 10.1086/511685
– ident: #cr-split#-e_1_2_14_204_1.2
– ident: e_1_2_14_274_1
  doi: 10.1128/AAC.00172-10
– ident: e_1_2_14_105_1
  doi: 10.1111/myc.12871
– ident: e_1_2_14_207_1
  doi: 10.1007/s00228-014-1733-7
– ident: e_1_2_14_232_1
  doi: 10.1080/14787210.2016.1207526
– ident: e_1_2_14_88_1
  doi: 10.1001/archdermatol.2009.362
– volume: 17
  start-page: 691
  year: 1978
  ident: e_1_2_14_285_1
  article-title: Ocular penetration of 5‐fluorocytosine
  publication-title: Invest Ophthalmol Vis Sci
– ident: e_1_2_14_92_1
  doi: 10.1182/blood-2012-01-403030
– ident: #cr-split#-e_1_2_14_156_1.1
– ident: e_1_2_14_218_1
  doi: 10.1128/AAC.00216-13
– ident: e_1_2_14_119_1
  doi: 10.1086/423381
– ident: e_1_2_14_47_1
  doi: 10.1136/bmj.322.7286.579
– ident: e_1_2_14_58_1
  doi: 10.1086/514672
– ident: e_1_2_14_214_1
  doi: 10.1586/14787210.2016.1128822
– ident: #cr-split#-e_1_2_14_31_1.2
– ident: e_1_2_14_83_1
  doi: 10.1177/0091270005283837
– ident: e_1_2_14_16_1
  doi: 10.1093/cid/ciw326
– ident: e_1_2_14_13_1
  doi: 10.1177/1078155217722405
– ident: e_1_2_14_21_1
  doi: 10.1007/BF00199879
– ident: e_1_2_14_84_1
  doi: 10.1016/S0140-6736(05)67490-9
– ident: e_1_2_14_202_1
  doi: 10.1007/s12281-017-0287-4
– ident: e_1_2_14_257_1
  doi: 10.1093/jac/dkx354
– ident: e_1_2_14_195_1
  doi: 10.5863/1551-6776-25.1.47
– ident: e_1_2_14_103_1
  doi: 10.1093/jac/dkx263
– ident: e_1_2_14_64_1
  doi: 10.1056/NEJMoa061098
– ident: e_1_2_14_80_1
  doi: 10.1056/NEJM200201243460403
– ident: e_1_2_14_124_1
  doi: 10.1038/sj.bmt.1704516
– ident: e_1_2_14_172_1
  doi: 10.1111/j.1469-0691.2009.02990.x
– ident: e_1_2_14_59_1
  doi: 10.1056/NEJMoa040446
– ident: #cr-split#-e_1_2_14_122_1.1
– ident: e_1_2_14_142_1
  doi: 10.1016/j.jinf.2006.03.003
– ident: e_1_2_14_187_1
  doi: 10.1128/AAC.01435-19
– ident: e_1_2_14_306_1
  doi: 10.1016/j.ijid.2016.12.014
– ident: e_1_2_14_115_1
  doi: 10.1016/S1473-3099(16)00071-2
– ident: e_1_2_14_170_1
  doi: 10.1128/AAC.05219-11
– ident: e_1_2_14_211_1
  doi: 10.1186/s13054-015-0758-3
– ident: e_1_2_14_216_1
  doi: 10.1128/AAC.01088-16
– ident: e_1_2_14_121_1
  doi: 10.1038/bmt.2009.334
– ident: e_1_2_14_143_1
  doi: 10.1016/j.bbmt.2012.03.014
– ident: e_1_2_14_125_1
  doi: 10.1111/j.1399-3062.2004.00065.x
– ident: e_1_2_14_298_1
  doi: 10.1111/myc.12199
– ident: e_1_2_14_108_1
  doi: 10.1210/js.2019-00189
– ident: e_1_2_14_243_1
  doi: 10.1177/0091270008327537
– ident: e_1_2_14_284_1
  doi: 10.1128/AAC.1.6.476
– ident: e_1_2_14_23_1
  doi: 10.1007/s13318-018-0519-1
– ident: e_1_2_14_96_1
  doi: 10.1097/RLU.0b013e31820902d8
– ident: e_1_2_14_24_1
  doi: 10.1128/AAC.01034-08
– ident: e_1_2_14_52_1
  doi: 10.1016/S0002-9343(99)00457-X
– ident: e_1_2_14_186_1
  doi: 10.1093/jac/dkz303
– ident: e_1_2_14_38_1
  doi: 10.1080/17425255.2019.1671971
– ident: e_1_2_14_135_1
  doi: 10.1128/AAC.50.2.632-638.2006
– ident: e_1_2_14_177_1
  doi: 10.1111/myc.12326
– ident: e_1_2_14_286_1
  doi: 10.1128/AAC.00949-10
– ident: e_1_2_14_85_1
  doi: 10.1086/324620
– ident: #cr-split#-e_1_2_14_122_1.2
– ident: e_1_2_14_95_1
  doi: 10.1111/j.1600-6143.2009.02837.x
– ident: e_1_2_14_66_1
  doi: 10.1182/blood-2003-08-2644
– ident: e_1_2_14_72_1
  doi: 10.1345/aph.1G741
– ident: e_1_2_14_153_1
  doi: 10.1592/phco.31.2.214
– ident: #cr-split#-e_1_2_14_204_1.1
– ident: e_1_2_14_34_1
– ident: e_1_2_14_111_1
  doi: 10.1128/AAC.02605-17
– ident: e_1_2_14_120_1
  doi: 10.1056/NEJMoa021585
– ident: e_1_2_14_60_1
  doi: 10.1034/j.1399-3062.2002.t01-2-02002.x
– ident: e_1_2_14_159_1
  doi: 10.1016/j.cmi.2018.01.002
– ident: e_1_2_14_281_1
  doi: 10.1086/377131
– ident: e_1_2_14_255_1
  doi: 10.1128/AAC.01034-17
– ident: e_1_2_14_137_1
  doi: 10.1086/423378
– ident: e_1_2_14_166_1
  doi: 10.1177/1078155218786028
– ident: e_1_2_14_78_1
  doi: 10.1016/S0002-9343(02)01191-9
– ident: e_1_2_14_41_1
  doi: 10.1097/QCO.0000000000000611
– ident: e_1_2_14_22_1
  doi: 10.1128/AAC.01723-18
– ident: e_1_2_14_82_1
  doi: 10.1093/jac/dkp464
– ident: e_1_2_14_260_1
  doi: 10.1128/AAC.11.2.244
– ident: e_1_2_14_212_1
  doi: 10.1111/bcp.13628
– ident: e_1_2_14_8_1
  doi: 10.1128/AAC.01316-08
– ident: e_1_2_14_3_1
  doi: 10.1093/jac/dkx029
– ident: e_1_2_14_55_1
  doi: 10.1046/j.1365-2141.1997.2473063.x
– ident: e_1_2_14_112_1
  doi: 10.1093/cid/ciz741
– ident: e_1_2_14_162_1
  doi: 10.1046/j.1365-2141.1999.01465.x
– ident: #cr-split#-e_1_2_14_245_1.1
– ident: e_1_2_14_63_1
  doi: 10.1182/blood-2005-06-2564
– ident: e_1_2_14_94_1
  doi: 10.3928/01477447-20110922-35
– ident: e_1_2_14_73_1
  doi: 10.1016/0002-9343(94)90023-X
– volume: 62
  start-page: e00885
  year: 2018
  ident: e_1_2_14_217_1
  article-title: Population pharmacokinetics and cerebrospinal fluid penetration of fluconazole in adults with cryptococcal meningitis
  publication-title: Antimicrob Agents Chemother
– ident: e_1_2_14_163_1
  doi: 10.1200/JCO.2003.04.052
– ident: e_1_2_14_68_1
  doi: 10.1128/AAC.43.8.1955
– ident: e_1_2_14_206_1
  doi: 10.1517/17425255.2011.615309
– ident: e_1_2_14_116_1
  doi: 10.1111/myc.12731
– ident: e_1_2_14_132_1
  doi: 10.1517/14740338.2013.829036
– ident: e_1_2_14_160_1
  doi: 10.1046/j.1439-0507.1999.00505.x
– ident: e_1_2_14_69_1
  doi: 10.1056/NEJM199411173312001
– ident: #cr-split#-e_1_2_14_32_1.2
– ident: e_1_2_14_171_1
  doi: 10.1128/AAC.00626-12
– ident: e_1_2_14_185_1
  doi: 10.1128/AAC.47.9.2788-2795.2003
– ident: e_1_2_14_228_1
  doi: 10.1128/AAC.00702-11
– ident: e_1_2_14_81_1
  doi: 10.1086/374557
– ident: e_1_2_14_266_1
  doi: 10.1128/AAC.32.3.369
– ident: #cr-split#-e_1_2_14_245_1.2
– ident: e_1_2_14_184_1
  doi: 10.1128/AAC.01027-09
– ident: e_1_2_14_65_1
  doi: 10.7326/0003-4819-138-9-200305060-00006
– ident: e_1_2_14_233_1
  doi: 10.1111/fcp.12212
– ident: e_1_2_14_287_1
  doi: 10.1128/AAC.00229-16
– ident: e_1_2_14_33_1
  doi: 10.1002/cpdd.588
– ident: e_1_2_14_236_1
  doi: 10.1097/QCO.0b013e3283184611
– ident: e_1_2_14_200_1
  doi: 10.1128/AAC.00496-15
– ident: e_1_2_14_147_1
  doi: 10.1038/bmt.2013.87
– ident: e_1_2_14_219_1
  doi: 10.1128/AAC.05900-11
– ident: e_1_2_14_277_1
  doi: 10.1038/bmt.2009.17
– ident: e_1_2_14_169_1
  doi: 10.1093/jac/dkw099
– ident: e_1_2_14_75_1
  doi: 10.1056/NEJMoa061094
– ident: e_1_2_14_289_1
  doi: 10.1128/AAC.48.3.815-823.2004
– ident: e_1_2_14_9_1
  doi: 10.1093/jac/dkv380
– ident: e_1_2_14_196_1
  doi: 10.1128/AAC.00484-19
– ident: e_1_2_14_164_1
  doi: 10.1128/AAC.35.4.707
– ident: e_1_2_14_110_1
  doi: 10.1128/AAC.00760-17
– ident: e_1_2_14_183_1
  doi: 10.1128/AAC.02353-18
– ident: e_1_2_14_182_1
  doi: 10.1128/AAC.02655-17
– ident: e_1_2_14_239_1
  doi: 10.1093/jac/dku529
– ident: e_1_2_14_299_1
  doi: 10.1016/j.mmcr.2013.04.001
– ident: e_1_2_14_292_1
  doi: 10.1111/imj.12594
– ident: e_1_2_14_129_1
  doi: 10.1111/j.1365-2710.2011.01309.x
– ident: e_1_2_14_225_1
  doi: 10.1111/myc.13028
– ident: e_1_2_14_51_1
  doi: 10.1093/clinids/20.4.755
– ident: e_1_2_14_151_1
  doi: 10.1159/000007260
– ident: e_1_2_14_167_1
  doi: 10.1093/ofid/ofv133.527
– ident: e_1_2_14_283_1
  doi: 10.1136/pgmj.55.647.667
– ident: e_1_2_14_61_1
  doi: 10.1086/323401
– ident: e_1_2_14_262_1
  doi: 10.1128/CMR.00046-13
– ident: e_1_2_14_157_1
  doi: 10.1093/jac/dkx295
– ident: e_1_2_14_11_1
  doi: 10.1093/jac/dkx228
– ident: e_1_2_14_90_1
  doi: 10.1086/588844
– ident: e_1_2_14_264_1
  doi: 10.1517/17425255.3.4.573
– ident: e_1_2_14_191_1
  doi: 10.1111/myc.12339
– ident: e_1_2_14_254_1
  doi: 10.1093/jac/dkx122
– ident: e_1_2_14_141_1
  doi: 10.1016/S0140-6736(07)60605-9
– ident: e_1_2_14_100_1
  doi: 10.1111/j.1365-2710.2007.00812.x
– ident: e_1_2_14_275_1
  doi: 10.1128/AAC.01284-09
– ident: e_1_2_14_40_1
  doi: 10.1093/jac/dkw047
– ident: e_1_2_14_139_1
  doi: 10.1007/s10096-012-1754-z
– ident: e_1_2_14_145_1
  doi: 10.1007/s00277-015-2545-2
– ident: e_1_2_14_138_1
  doi: 10.1111/j.1439-0507.2011.02116.x
– ident: e_1_2_14_140_1
  doi: 10.1086/422312
– ident: e_1_2_14_178_1
  doi: 10.1186/s12879-018-3055-3
– ident: #cr-split#-e_1_2_14_36_1.1
– ident: e_1_2_14_190_1
  doi: 10.1093/jac/dkz546
– ident: e_1_2_14_241_1
  doi: 10.1097/MPH.0b013e3182880eaa
– ident: e_1_2_14_209_1
  doi: 10.1093/ndt/gfg363
– ident: e_1_2_14_71_1
  doi: 10.1016/0959-8049(95)00619-2
– ident: e_1_2_14_176_1
  doi: 10.1038/clpt.2010.64
– ident: e_1_2_14_67_1
  doi: 10.1016/S0002-9343(96)80072-6
– ident: e_1_2_14_44_1
  doi: 10.1038/ki.1991.214
– ident: e_1_2_14_226_1
  doi: 10.1128/AAC.47.10.3165-3169.2003
– ident: e_1_2_14_230_1
  doi: 10.1002/phar.1631
– ident: e_1_2_14_6_1
  doi: 10.1038/sj.bmt.1701270
– ident: #cr-split#-e_1_2_14_32_1.1
– ident: e_1_2_14_240_1
  doi: 10.2217/pgs.14.53
– ident: e_1_2_14_50_1
  doi: 10.1002/j.1875-9114.1990.tb02593.x
– ident: e_1_2_14_131_1
  doi: 10.1111/jcpt.12078
– ident: e_1_2_14_10_1
  doi: 10.1111/myc.12452
– ident: e_1_2_14_247_1
  doi: 10.1128/AAC.01221-08
– ident: e_1_2_14_165_1
  doi: 10.1136/jcp.50.6.477
– ident: e_1_2_14_168_1
  doi: 10.1038/sj.bmt.1705754
– ident: e_1_2_14_222_1
  doi: 10.1016/j.drup.2014.06.001
– ident: e_1_2_14_223_1
  doi: 10.2147/TCRM.S203625
– volume-title: An Advanced Pharmacy Practice Framework for Australia
  year: 2012
  ident: e_1_2_14_296_1
– ident: e_1_2_14_215_1
  doi: 10.2165/00003088-200544100-00002
– volume: 7
  start-page: 10
  year: 2013
  ident: e_1_2_14_93_1
  article-title: Voriconazole‐induced periostitis in two post‐transplant patients
  publication-title: J Radiol Case Rep
– ident: e_1_2_14_15_1
  doi: 10.1128/AAC.00802-12
– ident: e_1_2_14_97_1
  doi: 10.1097/RHU.0b013e31820aff12
– ident: e_1_2_14_117_1
  doi: 10.1002/cpt.620
– ident: e_1_2_14_149_1
  doi: 10.1086/520980
– ident: e_1_2_14_150_1
  doi: 10.1093/jac/46.2.171
– ident: e_1_2_14_106_1
  doi: 10.1128/AAC.03050-14
– ident: e_1_2_14_144_1
  doi: 10.1128/AAC.49.4.1331-1336.2005
– ident: e_1_2_14_126_1
  doi: 10.1034/j.1399-3062.2002.01004.x
– ident: e_1_2_14_87_1
  doi: 10.1016/j.jaad.2009.09.033
– ident: e_1_2_14_127_1
  doi: 10.2165/11585270-000000000-00000
– ident: e_1_2_14_45_1
  doi: 10.1097/00000441-198911000-00004
– ident: e_1_2_14_194_1
  doi: 10.1007/s40262-018-0658-1
– ident: e_1_2_14_271_1
  doi: 10.1128/AAC.42.7.1738
– ident: e_1_2_14_297_1
  doi: 10.1016/j.cmi.2020.03.008
– ident: e_1_2_14_301_1
  doi: 10.1177/1078155217748471
– ident: e_1_2_14_20_1
  doi: 10.1186/1471-2407-10-679
– ident: e_1_2_14_42_1
  doi: 10.1002/14651858.CD000969
– ident: e_1_2_14_104_1
  doi: 10.1128/AAC.50.2.658-666.2006
– ident: e_1_2_14_210_1
  doi: 10.1186/s13054-014-0657-z
– ident: e_1_2_14_29_1
  doi: 10.2174/1389200215666141125121511
– ident: e_1_2_14_201_1
  doi: 10.1155/2014/340586
– ident: e_1_2_14_248_1
  doi: 10.1111/bcp.13789
– ident: e_1_2_14_249_1
  doi: 10.1128/AAC.00705-18
– ident: e_1_2_14_272_1
  doi: 10.1007/s10792-012-9696-0
– ident: e_1_2_14_290_1
  doi: 10.1248/bpb.27.1154
– ident: e_1_2_14_280_1
  doi: 10.1128/AAC.00394-13
– ident: e_1_2_14_252_1
– ident: e_1_2_14_99_1
  doi: 10.1345/aph.1H671
– ident: e_1_2_14_213_1
  doi: 10.1093/cid/ciu657
– ident: e_1_2_14_18_1
  doi: 10.1124/dmd.32.2.267
– ident: e_1_2_14_198_1
  doi: 10.1093/jac/dkaa382
– ident: e_1_2_14_48_1
  doi: 10.1086/313498
– ident: e_1_2_14_265_1
  doi: 10.1093/clinids/12.Supplement_3.S318
– ident: e_1_2_14_152_1
  doi: 10.1016/0002-9343(87)90691-7
– ident: e_1_2_14_293_1
  doi: 10.1097/FTD.0b013e3181ea3de6
– ident: e_1_2_14_238_1
  doi: 10.1128/AAC.01194-17
– ident: e_1_2_14_76_1
  doi: 10.1128/AAC.41.12.2714
– ident: e_1_2_14_89_1
  doi: 10.1155/2010/351084
– ident: e_1_2_14_261_1
  doi: 10.1093/clind/15.6.1003
– ident: e_1_2_14_244_1
  doi: 10.1002/cpt.583
– ident: e_1_2_14_282_1
  doi: 10.1136/bjo.2007.136515
– ident: e_1_2_14_27_1
  doi: 10.1093/mmy/myz012
– ident: e_1_2_14_231_1
  doi: 10.1093/jac/dkp416
– ident: e_1_2_14_79_1
  doi: 10.1111/myc.12749
– ident: e_1_2_14_263_1
  doi: 10.1128/AAC.37.6.1270
– ident: e_1_2_14_220_1
  doi: 10.1097/QCO.0b013e328359a56e
– ident: e_1_2_14_221_1
  doi: 10.1007/s12281-016-0255-4
– ident: e_1_2_14_114_1
  doi: 10.1016/S0140-6736(15)01159-9
– ident: e_1_2_14_133_1
– ident: e_1_2_14_148_1
– ident: e_1_2_14_54_1
  doi: 10.1086/317451
– ident: e_1_2_14_158_1
  doi: 10.1128/AAC.32.9.1310
– ident: e_1_2_14_250_1
  doi: 10.2147/DHPS.S140213
– ident: e_1_2_14_279_1
  doi: 10.1093/jac/dkm023
– ident: e_1_2_14_205_1
  doi: 10.1201/b13787-151
– ident: e_1_2_14_17_1
  doi: 10.1111/imj.12600
– ident: e_1_2_14_130_1
  doi: 10.1111/jcpt.12046
– ident: e_1_2_14_12_1
  doi: 10.1186/s12941-017-0235-8
– ident: e_1_2_14_208_1
  doi: 10.1093/jac/dkx447
– ident: #cr-split#-e_1_2_14_156_1.2
– ident: e_1_2_14_35_1
  doi: 10.1128/AAC.00701-16
– ident: e_1_2_14_25_1
  doi: 10.1002/j.1875-9114.1998.tb03856.x
– ident: e_1_2_14_43_1
  doi: 10.1007/s10096-005-0080-0
– ident: e_1_2_14_2_1
  doi: 10.1097/QCO.0000000000000497
– ident: e_1_2_14_224_1
  doi: 10.1007/s40265-020-01306-y
– ident: e_1_2_14_288_1
  doi: 10.1128/AAC.45.10.2845-2855.2001
– ident: e_1_2_14_14_1
  doi: 10.1097/FTD.0000000000000235
– ident: e_1_2_14_56_1
  doi: 10.1111/j.1600-0609.2004.00239.x
– ident: e_1_2_14_189_1
  doi: 10.1111/bcp.13707
– ident: e_1_2_14_28_1
  doi: 10.1517/14656566.6.13.2231
– ident: #cr-split#-e_1_2_14_118_1.1
– ident: e_1_2_14_237_1
  doi: 10.1128/AAC.00296-07
– ident: e_1_2_14_19_1
  doi: 10.1128/AAC.28.5.648
– ident: #cr-split#-e_1_2_14_36_1.2
– ident: e_1_2_14_98_1
  doi: 10.1093/cid/ciq188
– ident: e_1_2_14_136_1
  doi: 10.1056/NEJMoa066906
– ident: e_1_2_14_199_1
  doi: 10.1111/myc.12948
– ident: e_1_2_14_53_1
  doi: 10.7326/0003-4819-135-6-200109180-00010
– ident: e_1_2_14_256_1
  doi: 10.1093/jac/dkz188
– ident: e_1_2_14_267_1
  doi: 10.1002/j.1552-4604.1988.tb03159.x
– ident: e_1_2_14_273_1
  doi: 10.1128/AAC.31.1.6
– ident: e_1_2_14_37_1
  doi: 10.1086/598327
– volume: 2015
  start-page: 927496
  year: 2015
  ident: e_1_2_14_259_1
  article-title: Flucytosine pharmacokinetics in a critically ill patient receiving continuous renal replacement therapy
  publication-title: Case Rep Crit Care
– ident: e_1_2_14_302_1
  doi: 10.1111/myc.12524
– start-page: 223
  volume-title: Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents
  year: 1987
  ident: e_1_2_14_270_1
– ident: e_1_2_14_173_1
  doi: 10.1128/AAC.01083-10
– ident: #cr-split#-e_1_2_14_118_1.2
– ident: e_1_2_14_303_1
  doi: 10.1177/1078155216673228
– ident: e_1_2_14_57_1
  doi: 10.1086/341401
– ident: e_1_2_14_26_1
  doi: 10.1046/j.1365-2125.2003.01994.x
– ident: e_1_2_14_7_1
  doi: 10.1093/cid/cis599
– ident: e_1_2_14_235_1
  doi: 10.1128/AAC.42.6.1512
– ident: e_1_2_14_123_1
  doi: 10.1093/jac/dkl009
– ident: e_1_2_14_74_1
  doi: 10.1086/515129
– ident: e_1_2_14_102_1
  doi: 10.1086/504328
– ident: e_1_2_14_253_1
  doi: 10.1002/pbc.25568
– ident: e_1_2_14_294_1
  doi: 10.1016/j.ijantimicag.2020.106180
– ident: e_1_2_14_39_1
  doi: 10.1093/jac/dkv350
– ident: e_1_2_14_109_1
  doi: 10.1093/ckj/sfx156
– ident: e_1_2_14_181_1
  doi: 10.1128/AAC.05000-14
– ident: e_1_2_14_251_1
  doi: 10.1128/AAC.00700-12
– ident: e_1_2_14_4_1
  doi: 10.1093/jac/dkt508
– ident: #cr-split#-e_1_2_14_31_1.1
– ident: e_1_2_14_161_1
  doi: 10.1086/605499
– ident: e_1_2_14_179_1
  doi: 10.1097/FTD.0000000000000175
– ident: e_1_2_14_291_1
  doi: 10.1097/FTD.0000000000000334
– ident: e_1_2_14_295_1
  doi: 10.1002/jppr.1378
– ident: e_1_2_14_146_1
  doi: 10.1080/10428190802635500
– ident: e_1_2_14_46_1
  doi: 10.1086/341662
– ident: e_1_2_14_62_1
  doi: 10.1128/AAC.14.2.270
– start-page: 2919
  volume-title: Kucers' the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs
  year: 2017
  ident: e_1_2_14_258_1
– ident: e_1_2_14_234_1
  doi: 10.1128/AAC.49.8.3171-3177.2005
– ident: e_1_2_14_174_1
  doi: 10.1128/AAC.05937-11
– ident: e_1_2_14_246_1
  doi: 10.1002/cpt.1012
SSID ssj0017394
Score 2.5020638
Snippet Antifungal agents can have complex dosing and the potential for drug interaction, both of which can lead to subtherapeutic antifungal drug concentrations and...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 37
SubjectTerms Antifungal Agents
antifungal therapy
Cytochrome P450
Dosage
Drug delivery
Drug dosages
Drug interaction
Drug Interactions
Drug metabolism
Drug Monitoring
Gene polymorphism
Hematologic Neoplasms - drug therapy
Hematology
Hematopoietic Stem Cell Transplantation
Humans
Malignancy
Patients
pharmacogenomics
Stem cell transplantation
therapeutic drug monitoring
Toxicity
Title Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fimj.15587
https://www.ncbi.nlm.nih.gov/pubmed/34937141
https://www.proquest.com/docview/2612461110
https://www.proquest.com/docview/2613289881
Volume 51
WOSCitedRecordID wos000732933900004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library Full Collection 2020
  customDbUrl:
  eissn: 1445-5994
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017394
  issn: 1444-0903
  databaseCode: DRFUL
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9RAEB_aq4gvtX5Ur7ZlFB_6YODuNpts8EnUo5W2iFi5t7DZ7J2BXnJcklL_T_-gzmw-sNiC4FtgJ5sl87G_nd39DcBb5vggWD_2bCoTzw_NyEtSX3hBEOmxMgTpXTmgH6fh-bmazaKvG_C-uwvT8EP0CTf2DBev2cF1Uv7h5NmS3FxKFW7C1oTsVg5g69O36cVpv4kQClcHkZYMvktHtMRCfJCnf_n2dPQXxrwNWd2cM338X6Pdge0WauKHxjaewIbNn8LDs3Yz_Rn85mKdXOmixEXNbFd8Ah4JxGJBcYT0T7Maaj5MRAGBOkrX9QJZjKz_FzWkuHQBgTODWBWor4ospYdr6r9qBDKXsrBY1BUNmHrPcmyZXEvkFDD-1Ewa20VgXNKyYMEcIM373FqsioxvWiJTTiNvNGDlGNkvaWzI5Bwr1987nBCSeA4X08_fPx57bZEHzwgOcNZFASUDo0Lhi7kxUqYjHckkNFYorXxppElpGRgJaZVIdGQCoa2MjJ0HIhC7MMiL3L4EJCw2slwGSTLKC-YRoSctKCKZRNv5ZDKEo07XsWkZ0LkQx2XcrYRIS7HT0hDe9KKrhvbjLqH9zmDi1vPLmCnZ_IDkRkN43TeTzvj_6NwWtZMRtNBVajyEF42h9V8RPjMU-tRy5Ozp_s_HJ2df3MPev4u-gkesi-Yy5T4MqnVtD-CBuaqycn0Im-FMHbZudAPCWyL5
linkProvider Wiley-Blackwell
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB4tuwi48H4UFhgQhz1spLa2E0figoBqF9oKoV20t8hx3BJpm1RtsoL_yQ9ixnmIFSAhcYvkiWNlHv48tr8BeMUcHwTrR4HLVBrIyA6DNJMiCMPYjLQlSO_LAX2ZRvO5PjuLP-3A6-4uTMMP0Sfc2DN8vGYH54T0L16er8jPldLRFdiTZEZk33vvPk9Op_0uQiR8IURaM0ifj2iZhfgkT__y5fnoN5B5GbP6SWdy6_-GextutmAT3zTWcQd2XHEXrs3a7fR78IPLdXKtiy0ua-a74jPwSDAWS4okZAE0r6Hh40QUEqijbFMvkcXI_r9TQ4YrHxI4N4hVieaizDN6-Eb9V41A7pMWDsu6ohFT73mBLZfrFjkJjF8N08Z2MRhXtDBYMgtI8z63lusy57uWyKTTyFsNWHlO9nMaGzI9x9r3d4hjwhL34XTy_uTtUdCWeQis4BDnfBzQKrQ6ElIsrFUqG5pYpZF1QhstlVU2o4VgLJTTIjWxDYVxKrZuEYpQPIDdoizcI0BCY0PHhZAU47xwERN-MoJikk2NW4zHAzjolJ3YlgOdS3GcJ91aiLSUeC0N4GUvum6IP_4ktN9ZTNL6_jZhUjYZktxwAC_6ZtIZ_x9TuLL2MoKWulqPBvCwsbT-K0IyR6GklgNvUH__fHI8--AfHv-76HO4fnQymybT4_nHJ3CD9dJcrdyH3WpTu6dw1V5U-XbzrPWmnzoAJgE
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VLaq48GxhocCAeuiBSLvrOHEkLoiyorBdVahFvUWO4yyRuslqN6ngf_KDmHEeogKkStwieeJYmYc_j-1vAA6Y44Ng_dizqUw8PzQjL0l94QVBpMfKEKR35YC-zsL5XF1cRKdb8La7C9PwQ_QJN_YMF6_Zwe0qzX7z8nxJfi6lCm_Bts9FZAawffRlej7rdxFC4Qoh0prBd_mIllmIT_L0L1-fj_4Amdcxq5t0pvf-b7j34W4LNvFdYx0PYMsWD2HnpN1OfwQ_uVwn17rY4KJmvis-A48EY7GkSEIWQPMaaj5ORCGBOkrX9QJZjOz_BzWkuHQhgXODWJWor8o8pYfv1H_VCOQuaWGxrCsaMfWeF9hyuW6Qk8D4TTNtbBeDcUkLgwWzgDTvc2u5KnO-a4lMOo281YCV42S_pLEh03OsXH9vcEJYYhfOpx_O3n_02jIPnhEc4qyLA0oGRoXCF5kxUqYjHckkNFYorXxppElpIRgJaZVIdGQCoa2MjM0CEYg9GBRlYZ8AEhobWS6EJBnnBVlE-EkLikkm0TabTIZw2Ck7Ni0HOpfiuIy7tRBpKXZaGsLrXnTVEH_8TWi_s5i49f1NzKRsfkByoyG86ptJZ_x_dGHL2skIWuoqNR7C48bS-q8InzkKfWo5dAb178_Hxyef3MPTm4u-hJ3To2k8O55_fgZ3WC3Nzcp9GFTr2j6H2-aqyjfrF60z_QKO-iV8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Consensus+guidelines+for+optimising+antifungal+drug+delivery+and+monitoring+to+avoid+toxicity+and+improve+outcomes+in+patients+with+haematological+malignancy+and+haemopoietic+stem+cell+transplant+recipients%2C+2021&rft.jtitle=Internal+medicine+journal&rft.au=Chau%2C+Maggie+M&rft.au=Daveson%2C+Kathryn&rft.au=Alffenaar%2C+Jan-Willem+C&rft.au=Gwee%2C+Amanda&rft.date=2021-11-01&rft.eissn=1445-5994&rft.volume=51+Suppl+7&rft.spage=37&rft_id=info:doi/10.1111%2Fimj.15587&rft_id=info%3Apmid%2F34937141&rft.externalDocID=34937141
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1444-0903&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1444-0903&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1444-0903&client=summon